Transient receptor potential melastatin 8 (TRPM8) antagonists and related methods

Novel TRPM8 antagonists with high potency and selectivity, designed through molecular dynamics simulations, address the limitations of current TRPM8 antagonists by effectively inhibiting TRPM8 activity and reducing pain responses in preclinical models.

JP7587276B2Active Publication Date: 2024-11-20MARSHALL UNIVERSITY RESEARCH CORP
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
JP2021544656
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-12-13
Filing Date
2020-01-31
Publication Date
2024-11-20
Estimated Expiration
2040-01-31

AI Technical Summary

Technical Problem

Current TRPM8 antagonists lack potency, specificity, and have not advanced to clinical use, necessitating the development of more effective compounds to treat pain conditions such as neuropathic pain, migraine, and other diseases mediated by TRPM8.

Method used

Development of novel TRPM8 antagonists with high nanomolar potency and modest selectivity, designed using molecular dynamics simulations and based on the avian cryoEM structure, targeting specific binding sites in the TRPM8 channel.

Benefits of technology

The novel TRPM8 antagonists effectively inhibit TRPM8 activity, reducing pain responses in preclinical models of neuropathic pain and other conditions, offering potential therapeutic benefits beyond existing compounds.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007587276000054
    Figure 0007587276000054
  • Figure 0007587276000055
    Figure 0007587276000055
  • Figure 0007587276000056
    Figure 0007587276000056
Patent Text Reader

Abstract

Provided herein are TRPM8 antagonists comprising the following formula (I): In formula (I), R1 is selected from a cycloalkyl, bicycloalkyl, or tricycloalkyl group. Each R1 group contains 5 to 12 carbon atoms. Furthermore, each R1 group is optionally substituted with an alkyl group containing 1 to 5 carbon atoms or a cycloalkyl group containing 4 to 12 carbon atoms, and each R1 group is optionally saturated or partially unsaturated. Further provided are methods for treating pain, the methods comprising administering to a subject in need thereof an effective amount of a TRPM8 antagonist comprising formula (I).
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] Related Applications

[0001] This application claims priority from U.S. Provisional Patent Application No. 62 / 800,114, filed February 1, 2019, U.S. Provisional Patent Application No. 62 / 800,143, filed February 1, 2019, and U.S. Provisional Patent Application No. 62 / 947,742, filed December 13, 2019, the entire disclosures of each of which are incorporated herein by this reference.

[0002] Technical Field

[0002] The presently disclosed subject matter relates generally to transient receptor potential melastatin 8 (TRPM8) antagonists and related methods. In particular, certain embodiments of the presently disclosed subject matter relate to TRPM8 antagonists and methods of using these antagonists for the treatment of pain. [Background technology]

[0003]

[0003] TRPM8, often referred to as the "cold receptor," is a polymodal nociceptor in the somatosensory nervous system and the primary detector of cold nociception in humans. Although distinct from other thermosensitive TRP channels, TRPA1 and TRPV1, TRPM8 is expressed in primary sensory neurons (Aδ and C fibers) of the dorsal root ganglion (DRG) and trigeminal ganglion (TG), as well as in several other non-neuronal tissues. Within primary sensory neurons, TRPM8 is present in both peripheral and central nerve terminals, supporting its role in somatosensory and central nervous systems. These cold-sensing nociceptors initiate sensory nerve action potentials following activation by mildly cool temperatures (15–25°C), chemicals such as (-)-menthol ((1R,2S,5R)-5-methyl-2-(1-methylethyl)-cyclohexanol), the "superagonist" icilin (3-(2-hydroxyphenyl)-6-(3-nitrophenyl)-3,4-dihydropyrimidin-2(1H)-one, also known as AG3-5), and the endogenous lipid PIP2. Maximal stimulation of TRPM8 by menthol occurs via a ligand stoichiometry of four menthol molecules occupying each monomer of one functional TRPM8 tetramer.

[0004]

[0004] TRPM8 is seen as a potential target for multiple therapeutic interventions: TRPM8 agonists are being explored for benign prostatic hyperplasia and prostate cancer, while antagonists are of growing interest for cold hypersensitivity in neuropathic pain and migraine, among others.

[0005]

[0005] There are several proprietary TRPM8 antagonists, many discovered through high-throughput screening of in-house chemical libraries, but how these antagonists bind to human TRPM8 and subsequently affect its gating mechanism, as well as the precise molecular details of their underlying pharmacophores, remain to be elucidated, especially given recent successes in TRPM8 and TRP channel structural biology revealed by cryo-electron microscopy (cryo-EM).

[0006]

[0006] TRPM8-mediated Ca 2+ In flux assays, known TRPM8 antagonists appear to exhibit modest or variable potency. For example, the quinoline-based PF-05105679 (Pfizer, Phase 1, NCT01393652) inhibited voltage- and WS-12-mediated activation effects at human TRPM8 with IC values ​​of 103 ± 9.4 nM and 181 ± 7.21 nM. 50 The 5,6,7,8-tetrahydro-1,7-naphthyridine analog AMG2850 (Amgen) inhibited menthol, icilin, and cold activation in rat and human TRPM8 with IC values ​​ranging from 7 to 156 nM. 50 The 2-benzyloxy-benzoic acid amide derivative AMTB (Bayer) inhibited the pIC 50 To date, however, no TRPM8 antagonists have been used in clinical trials. For example, PF-05105679 has an IC 50 It does not have a measurable therapeutic index at the high doses (600 mg and 900 mg) required to achieve unbound plasma concentrations greater than 100 mg. Similarly, a Phase 1 study of the nicotinic acid analog AMG333 (Amgen, NCT02132429) was discontinued for undisclosed reasons. There remains a need to introduce more TRPM8 antagonists that are potent, reasonably specific, and thus maintain the potential to successfully progress through clinical trials after successful preclinical development.

[0007]

[0007] Furthermore, a wide variety of both agonist and antagonist scaffolds with broad chemical diversity have been used to elucidate the role of TRPM8 in various disease states, such as orofacial and neuropathic pain, overactive bladder (OAB) and painful bladder syndrome, disorders involving temperature regulation, oral squamous cell carcinoma, nicotine addictive behavior, and chronic obstructive pulmonary disease. In some cases, the use of these ligands as tool molecules to probe the pharmacology of TRPM8 has led to conflicting data, particularly in determining its role in chronic neuropathic pain. Highly potent chemical probes based on the cognate ligand (-)-menthol with an antagonist profile are needed to bring the TRPM8 field back from the background of early drug development, but no such small molecules of this chemical class currently exist.

[0008]

[0008] Both apo- and agonist-bound avian TRPM8 (TRPM8 FA Recent cryo-EM structures of menthol and icilin (PDB codes 6BPQ (4.1 Å), 6NR2 (4 Å), and 6NR3 (3.4 Å)) point to critical binding sites for prototypic ligands, menthol and icilin, that may be uncoupled from cold sensing, as supported by in vitro and in vivo mutagenesis studies in mouse, rat, squirrel, and human orthologues. Mutagenesis studies have revealed that the conserved Tyr745, located in the middle of the transmembrane S1 helix of the voltage sensor-like domain (VSLD), [ 3These findings suggest that this region is important for both menthol binding and efficacy, as determined by radioligand displacement studies using [H]-menthol. These studies are consistent with the structure of avian TRPM8 (PDB 6NR2) complexed with the menthol analog WS-12. Assembly of the isolated S1-S4 sensing domain also suggests that this region is important for menthol recognition, as determined by microscale thermophoresis and NMR. Other menthol-sensitive residues include Tyr1005 and Leu1009, both of which are conserved in the TRP helix-transmembrane domain near the cytosolic domain interface. Positional equivalents of these two residues are also present in the WS-12-bound structure (TRPM8). FA This pocket can be seen at the S3 helix (Tyr1004 and Leu1008 in the S3 helix). This pocket also binds icilin at Gly805, Asn799, and Asp802 in the S3 helix, along with similar residues including Tyr745 and Leu1009. The cryo-EM structure of avian TRPM8 bound to icilin reveals that Tyr745, a conserved residue across all TRPM subtypes, is a common TRPM8 residue for both menthol and icilin recognition, despite their different chemical species, while Asn799 and Asp802, along with Gln782 and Glu785, are Ca2+-binding sites. 2+This strengthens the notion that TRPM8 is required for icilin-dependent binding. Additional icilin-binding residues, including Phe838, Arg841, His844, and Tyr1004 (Phe839, Arg842, His845, and Tyr1005 in hTRPM8, respectively), align to form an orthosteric site within the VSLD and TRP helices. This ligand-binding site also overlaps with a key voltage- and cold-sensing residue, conserved Arg841 (Arg842 in hTRPM8) in the S4 helix, indicating that the ability of TRPM8 to function as a multisensor of ligand and voltage stimuli derives, in part, from this common site within the S1-S4 helices in the VSLD. Transgenic models of hibernating ground squirrels and rats implicate residues responsible for cold activation relative to icilin activation scattered throughout the VSLD in the loop connecting the pore helix (PH) and S6 helix at positions 726 (pre-S1 domain), 762 (S1-S2 loop), 819 (S3-S4 loop), and the loop connecting the TM helices at positions 927, 946, and 947. Sequence alignment of rat, squirrel, and human TRPM8 orthologues revealed that four of the six cold-conferring residues in rat are conserved in the human orthologue (Tyr726, Ser762, Ser819, and Asn947), raising the possibility that ligand-to-cold activation in humans occurs in topographically distinct regions. On the other hand, the remaining two mismatched residues are conserved in humans and cold-tolerant ground squirrels (Ala927, His946), suggesting that these residues either do not support the cold-sensing phenotype or contribute to the cold response through allosteric regulation.

[0009]

[0009] Therefore, in light of the above studies, additional TRPM8 antagonists useful in the treatment of pain would be highly desirable and beneficial. Summary of the Invention [Means for solving the problem]

[0010]

[0010] The presently disclosed subject matter meets some or all of the above needs, as will become apparent to those skilled in the art after reviewing the information provided herein.

[0011]

[0011] This Summary describes several embodiments of the presently disclosed subject matter and often lists variations and permutations of these embodiments. This Summary is merely exemplary of many possible embodiments. Mention of one or more representative features of an embodiment is likewise exemplary. Such an embodiment can typically exist with or without the mentioned feature. Likewise, these features may be applicable to other embodiments of the presently disclosed subject matter whether or not they are listed in this Summary. To avoid excessive repetition, this Summary does not list or suggest all possible combinations of such features.

[0012]

[0012] In some embodiments of the presently disclosed subject matter, a compound of formula (I): [ka] wherein R1 is selected from a cycloalkyl, bicycloalkyl, or tricycloalkyl group, each of which may be saturated or partially unsaturated, having 5 to 12 carbon atoms, and which may be substituted with an alkyl group having 1 to 5 carbon atoms or a cycloalkyl group having 4 to 12 carbon atoms. In some embodiments, R1 is a bicycloalkyl group, and the bicycloalkyl group is a fused, bridged, or spiro-linked bicycloalkyl group. In some embodiments, R1 is a cycloalkyl group, for example, a cycloalkyl group that, in certain embodiments, is a branched or substituted cycloalkyl group.

[0013]

[0013] In some embodiments of the compounds of Formula (I), R1 is [ka] and analogs thereof.

[0014]

[0014] In some embodiments, R1 is [ka] and analogs thereof.

[0015]

[0015] In a further embodiment, R1 is [ka] and analogs thereof.

[0016]

[0016] In some embodiments, R1 is [ka] and analogs thereof.

[0017]

[0017] In some embodiments, R1 is [ka] and analogs thereof.

[0018]

[0018] In some embodiments, R1 is [ka] and analogs thereof.

[0019]

[0019] In some embodiments, R1 is [ka] and analogs thereof.

[0020]

[0020] In some embodiments of the presently disclosed subject matter, pharmaceutical compositions are further provided. In some embodiments, pharmaceutical compositions are provided that include a TRPM8 antagonist of the presently disclosed subject matter (e.g., a TRPM8 antagonist of Formula (I)) and a pharmaceutically acceptable vehicle, carrier, or excipient.

[0021]

[0021] In some embodiments of the presently disclosed subject matter, methods for treating pain are further provided. In some embodiments, a method for treating pain is provided, comprising administering to a subject in need thereof an effective amount of a TRPM8 antagonist comprising Formula (I) above. In some embodiments of this method of treatment, the pain is neuropathic pain, such as, in certain embodiments, allodynia, chronic neuropathic pain, or chemotherapy-induced neuropathic pain. In some embodiments, administering the TRPM8 antagonist can include intravenous, intraperitoneal, intramuscular, or subcutaneous injection of the TRPM8 antagonist. In some embodiments, the subject is a human.

[0022]

[0022] Further features and advantages of the present invention will become apparent to those skilled in the art after reviewing the present written description, drawings and non-limiting examples. [Brief explanation of the drawings]

[0023] [Figure 1]

[0023] Figure 1 is a chart showing reported TRPM8 antagonists, including IC50 values ​​for the antagonists determined in a Ca2+ flux assay on the effects of menthol and / or icilin (icilin: 3-(2-hydroxyphenyl)-6-(3-nitrophenyl)-3,4-dihydropyrimidin-2(1H)-one). [Figure 2]

[0024] Figures 2A-2D contain diagrams and graphs showing the convergence parameters of (-)-menthyl 1 and hTRPM8 during MD simulations, including: (Figure 2A) Diagram showing the docking pose (pre-MD) of compound 1 in hTRPM8, where (-)-menthyl compound 1 is shown as a magenta stick, key residues are shown as sticks, individual helices are indicated (1 (blue), S2 (faded green), S4 (yellow-green), TRP helix (red)), and Ca ions (green) are shown in the CPK representation; (Figure 2B) 100 ns Figure 2C shows the binding mode of compound 1 in hTRPM8 after MD (post-MD), where (-)-menthyl compound 1 is shown as a gray bar; (Figure 2C) is a graph showing the root mean square deviation (RMSD) of compound 1 and hTRPM8 during MD simulation; (Figure 2D) is a graph showing the energy decomposition of key residues in hTRPM8 that contribute to the binding of compound 1, where the hTRPM8 homology model was constructed using the cryo-EM structure of TRPM8FA (PDB 6BPQ) as a template. [Figure 3]

[0025] Figures 3A-3D contain diagrams and images showing the convergence parameters of AMG2850 and hTRPM8 during MD simulations, including: (Figure 3A) Diagram showing the docking pose (pre-MD) of AMG2850 in hTRPM8, where AMG2850 is shown as a magenta stick, key residues are shown as sticks, individual helices are indicated (S2 (faded green), S3 (green), S4 (yellow-green), TRP helix (red)), and Ca ions (green) are shown in the CPK representation; (Figure 3B) 100 ns Figure 3C shows the binding mode of AMG2850 in hTRPM8 after MD (post-MD), where AMG2850 is shown as a gray bar; (Figure 3C) is a graph showing the RMSD of AMG2850 and hTRPM8 during MD simulation; (Figure 3D) is a graph showing the energy decomposition of key residues in hTRPM8 that contribute to AMG2850 binding, where the hTRPM8 homology model was constructed using the cryo-EM structure of TRPM8FA (PDB 6BPQ) as a template. [Figure 4]

[0026] FIG. 4 shows the superposition of AMG2850 and (-)-menthyl compound 1 from their MD poses (green and magenta: MD poses of TRPM8 and (-)-menthyl compound 1, blue and gray: MD poses of TRPM8 and AMG2850). [Figure 5]

[0027] Figure 5 is a graph showing the evaluation of test compounds for any effect on icilin-induced Ca2+ entry signals using fura-2-based Ca2+ imaging of HEK-293 cells stably expressing human TRPM8, where fura-2-loaded cells bathed in Ca2+-free extracellular solution were exposed to icilin (500 nM) with or without various concentrations of synthetic compounds or the known TRPM8 antagonist RQ-00203078 (all 3 nM for this figure; corresponding histograms are shown in Figure 15). Approximately 4 min after compound addition, the Ca2+-free bath solution was replaced with one containing 2 mM Ca2+, where Ca2+ influx was monitored as the fura-2 fluorescence ratio (F355 / F380). Each data point represents the mean ± SEM (n ≥ 35 cells from three independent experiments performed on three different days). [Figure 6]

[0028] Figures 6A-6B include images showing the binding modes of compound 5 (Figure 6A) and compound 7 (Figure 6B) in hTRPM8, where compounds 5 and 7 are shown as yellow and orange sticks, respectively, key residues are shown as sticks, individual helices are indicated (S1 (blue), S2 (faded green), S4 (yellow-green), and TRP helix (red)), Ca ions (green) are shown in CPK representation, and an hTRPM8 homology model was constructed using the cryo-electron microscopy (cryo-EM) structure of TRPM8FA (PDB 6BPQ) as a template. [Figure 7]

[0029] 7A-7B include graphs showing inhibition of menthol-induced TRPM8 currents by compound 14, where currents were measured by whole-cell patch clamp electrophysiology of HEK-293 cells transiently transfected with human TRPM8, including: (FIG. 7A) average current traces (n=4) measured with a +80 mV voltage pulse upon exposure to a saturating concentration of 500 μM menthol and various concentrations of compound 14; (FIG. 7B) dose response of compound 14 measured at +80 mV in the presence of 500 μM menthol at concentrations ranging from 1 nM to 1 μM, where current responses were normalized to the maximum current magnitude measured without antagonist for each cell, data were fitted using a single-binding-site Hill equation, and an IC50 of 64 ± 2 nM (n=6 cells) was calculated; error bars indicate the standard error of the mean. [Figure 8]

[0030] Figures 8A-8D contain figures and graphs showing the convergence parameters of 14 and hTRPM8 during MD simulations, including the following: (Figure 8A) Graph showing the binding mode of compound 14 in hTRPM8 (pre-MD), where compound 14 is shown as a magenta stick, and key residues are shown as sticks, with individual helices (S1 (blue), S2 (faded green), S3 (green), S4 (yellow-green), TRP helix (red)) and Ca ions (green) shown in CPK representation; (Figure 8B) Graph showing the binding mode of compound 14 in hTRPM8 (post-MD); (Figure 8C) Graph showing the RMSD of compound 14 and hTRPM8; and (Figure 8D) Graph showing the energy decomposition of key residues in hTRPM8 that contribute to the binding of compound 14, where the hTRPM8 homology model was built using the cryo-EM structure of TRPM8FA (PDB 6BPQ) as a template. [Figure 9]

[0031] Figure 9 includes associated diagrams showing the binding pockets of compound 14 in TRPM8, TRPA1, and TRPV1 and their binding modes, including: (panel (a)) a diagram showing the location of the binding pocket of compound 14 in TRPM8, TRPA1, and TRPV1; (panel (b)); a diagram showing the binding mode of compound 14 in hTRPA1 (PDB 3J9P); (panel (c)) a diagram showing the binding mode of compound 14 in hTRPM8, where the hTRPM8 homology model was built using the cryo-electron microscopy (cryo-EM) structure of TRPM8FA (PDB 6BPQ) as a template; and (panel (d)) a diagram showing the binding mode of compound 14 in hTRPV1 (PDB 3J5R). [Figure 10]

[0032] Figure 10 is a graph showing the effect of compound 14 on icilin-induced wet-dog shakes (WDS) in ICR (CD1) mice, where the compound or vehicle was administered 30 minutes before icilin injection, gabapentin (25 mg / kg) was administered 1 hour before icilin injection, and the number of WDS was counted for 30 minutes after icilin (10 mg / kg) ip injection. Data are shown as mean ± SEM (n = 6) (two-way ANOVA with Bonferroni post-hoc test, **P < 0.01). [Figure 11]

[0033] Figure 11 is a graph showing the effect of compound 14 on oxaliplatin (OXP)-induced cold allodynia in male C57 mice, where mice were given three i.p. injections of OXP (6 mg / kg) or vehicle (saline and 5% mannitol solution, black line (control)) every other day, and cold allodynia was assessed by the acetone test on day 7 after administration. The time course of cold allodynia is shown for no compound injection (green line) or injection of 0.1 μg (blue line) or 1.0 μg (red line) of compound 14. Data are shown as mean ± SEM n=6 (one-way ANOVA with Dunnett's post-hoc test. *P<0.05; ***P<0.001****P<0.0001). [Figure 12]

[0034] FIG. 12 shows a sequence alignment of the S1-S4 helices (VSLD), S5-S6 helices (pore domain), pore helix (PH), and TRP helices for TRPM8 from the collared flycatcher (avian), human, and rat. The VSLD domains (S1-S4), pore domains (S5-S6 and pore helix PH), and TRP helices from the full-length sequences of TRPM8FA (U3JD03, 1103 residues), hTRPM8 (Q7Z2W7, 1104 residues), and rTRPM8 (Q8R455, 1104 residues) were obtained from UniProtKB / Swiss-Prot, and the three domains were aligned using Clustal Alignment using the Omega program, in which similar amino acids are highlighted, shows that TRPM8FA is highly homologous to human and rat TRPM8 in the above regions (86% and 87% sequence identity, respectively). Asterisks indicate residues sensitive to menthol (green), icilin (yellow), voltage (gold), and Ca2+ (magenta). [Figure 13]

[0035] Figure 13 is a graph showing the concentration-response curve for icilin in HEK293 cells stably expressing hTRPM8, where the response is reported as the peak fluorescence (Fura-2) ratio indicating the maximal change in intracellular free Ca2+ concentration at the indicated icilin concentration, and each data point represents the peak fluorescence ratio as the mean ± SEM (n≧30 cells from three independent experiments performed on three different days). [Figure 14]

[0036] Figure 14 is a graph showing the concentration-response curve of (-) menthol-induced Ca2+ entry in HEK-293-hTRPM8 cells, where each data point represents the mean response at the cognate concentration expressed as a percent of maximal Ca2+ entry in a Fura-2-based Ca2+ imaging assay, error bars represent SEM (n≧35 cells from three independent experiments performed on three different days), and the line represents a four-parameter logistic curve fit performed using Prism7 (Graphpad Inc.). [Figure 15]

[0037] FIG. 15 includes graphs showing the evaluation of the effects of compounds on icilin-induced Ca2+ entry in HEK-293 cells stably expressing human TRPM8, where each bar represents the peak Fura-2 ratio normalized to that of the icilin (500 nM) response and expressed as the mean ± SEM (n≧35 cells from three independent experiments performed on three different days); one-way ANOVA followed by Dunnett's test was used to compare the efficacy of test compounds to that of the control (icilin) ​​(*P<0.001). [Figure 16]

[0038] FIG. 16 is a graph showing the concentration-response curve of RQ-00203078, where the response is reported as the peak fluorescence (Fura-2) ratio normalized to the peak response elicited by 500 nM icilin alone, and each data point represents the mean ± SEM (n≧30 cells from three independent experiments performed on three different days). [Figure 17]

[0039] Figure 17 is a graph showing the concentration-response curve of compound 14, where the response is reported as the peak fluorescence (Fura-2) ratio normalized to the peak response evoked by 500 nM icilin alone, and each data point represents the mean ± SEM (n > 30 cells from three independent experiments performed on three different days). [Figure 18A]

[0040] Figure 18A is a graph showing typical traces illustrating the effect of compound 14 (3 nM) on (-)-menthol (100 μM)-induced Ca2+ entry signals using Fura-2-based Ca2+ imaging in HEK-293-hTRM8 cells, where each data point represents the mean ± SEM (n≧35 cells from three independent experiments performed on three different days). [Figure 18B]

[0041] Figure 18B is a graph showing the evaluation of the effect of 3 nM compound 14 on (-)menthol-evoked Ca2+ entry in HEK-293-hTRPM8, where each bar represents the peak Fura-2 ratio normalized to that of the menthol (100 μM) response and expressed as the mean ± SEM (n≧35 cells from three independent experiments performed on three different days), and the mean responses between the two groups were compared using Student's unpaired two-tailed t-test. [Figure 19]

[0042] FIG. 19 is a graph showing the intrinsic hTRPM8 activity of selected biphenylamide analogs, where Fura-2-based ratiometric Ca2+ imaging was performed using a Ca2+ (2 mM)-containing extracellular solution, and each data point represents the mean ± SEM (n≧20 cells from three independent experiments performed on three different days). [Figure 20]

[0043] FIG. 20 is a graph showing the agonist dose response of AITC activation of hTRPA1m, where EC50=7.62±0.89 μM, and each data point represents the mean±SEM, n=5 or 10 independent experiments. [Figure 21]

[0044] FIG. 21 is a graph showing ruthenium red blockade of AITC-activated (10 μM) hTRPA1 responses, where IC50=162±33 nM, and each data point represents the mean±SEM, n=5 independent experiments. [Figure 22]

[0045] FIG. 22 is a graph showing the agonist dose response of capsaicin activation of hTRPV1, where EC50=19±2.5 nM, and each data point represents the mean±SEM, n=5 or 10 independent experiments. [Figure 23]

[0046] FIG. 23 is a graph showing capsazepine blockade of capsaicin-activated (100 nM) hTRPV1 responses, where IC50=451±48 nM, and each data point represents the mean±SEM, n=5 independent experiments. DETAILED DESCRIPTION OF THE INVENTION

[0024]

[0047] Details of one or more embodiments of the presently disclosed subject matter are set forth in this document. Modifications to the embodiments described herein, as well as other embodiments, will become apparent to those skilled in the art after reviewing the information provided herein. The information provided herein, particularly the specific details of the exemplary embodiments described, is provided primarily for clarity of understanding, and no unnecessary limitations should be understood therefrom. In the case of conflict, the provisions of this document, including definitions, will control.

[0025]

[0048] Although the terms used herein are believed to be well understood by those of ordinary skill in the art, certain definitions are provided to facilitate explanation of the presently disclosed subject matter.

[0026]

[0049] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

[0027]

[0050] All patents, patent applications, published applications and publications, GenBank sequences, UniProt or Swiss-Prot databases, websites and other publications mentioned throughout this disclosure are incorporated by reference in their entirety unless otherwise stated.

[0028]

[0051] When referring to a URL or other such identifier or address, it is understood that such identifiers may change and specific information on the Internet may vary, but equivalent information may be found by searching the Internet, and reference thereto indicates that such information is available and publicly disseminated.

[0029]

[0052] As used herein, abbreviations for any protecting groups, amino acids, and other compounds follow their normal usage, recognized abbreviations, or the IUPAC-IUB Commission on Biochemical Nomenclature (see Biochem. 1972) 11(9):1726-1732) unless otherwise stated.

[0030]

[0053] Although any methods, devices, and materials similar or equivalent to those described herein can be used in the practice or testing of the presently disclosed subject matter, representative methods, devices, and materials are described herein.

[0031]

[0054] This application may "comprise" (open-ended), "consist" (close-ended), or "consist essentially of" the components of the presently disclosed subject matter and other materials or elements described herein. As used herein, "comprising" is open-ended and means the recited elements or their equivalents in structure or function, plus any other element or elements not recited. The terms "having" and "comprising" are also to be construed as open-ended unless the context suggests otherwise.

[0032]

[0055] Following long-standing patent law convention, the terms "a," "an," and "the" refer to "one or more" when used in this application, including the claims. Thus, for example, a reference to "a cell" includes a plurality of such cells, and so forth.

[0033]

[0056] Unless otherwise indicated, all numbers expressing quantities of materials, properties, reaction conditions, and the like used in the specification and claims are to be understood as being modified in all instances by the term "about." Accordingly, unless otherwise indicated, the numerical parameters set forth in the specification and claims are approximations that may vary depending upon the desired properties sought to be obtained by the presently disclosed subject matter.

[0034]

[0057] As used herein, the term "about," when referring to a value or amount of mass, weight, time, volume, concentration, or percentage, is meant to include variations of ±20%, in some embodiments ±10%, in some embodiments ±5%, in some embodiments ±1%, in some embodiments ±0.5%, and in some embodiments ±0.1% of the specified amount, as such variations are appropriate for performing the disclosed methods.

[0035]

[0058] As used herein, ranges can be expressed as from "about" one particular value and / or to "about" another particular value. Several values ​​are disclosed herein, and it is understood that each value is also disclosed herein as "about" that particular value, along with the value itself. For example, if the value "10" is disclosed, then "about 10" is also disclosed. Each unit between two particular units is also understood to be disclosed. For example, if 10 and 15 are disclosed, then 11, 12, 13, and 14 are also disclosed.

[0036]

[0059] As used herein, "optionally" or "optionally" means that the subsequently described event or circumstance may or may not occur, and that the description includes cases where the event or circumstance occurs and cases where it does not occur. For example, an optionally variable moiety means that the moiety may vary or may not vary.

[0037]

[0060] The presently disclosed subject matter is based, at least in part, on the development of small molecule TRPM8 antagonists that share both structural similarity and conformational stability with the avian cryo-EM structure of TRPM8. FAPoses from molecular dynamics (MD) simulations on a human TRPM8 homology model based on the ATPase (PDB 6BPQ, approximately 4.1 Å) were used to reveal similar molecular determinants for ligand recognition. These insights enabled the design of novel TRPM8 chemical probes and therapeutic compounds for TRPM8-mediated sensory neuropathies, which, in some embodiments, were identified as having greater potency than currently known TRPM8 antagonists, such as the 2-benzyloxy-benzoic acid amide derivative AMTB and TRPV1 antagonists with bifunctional TRPM8 antagonist activity, such as the pyridylpiperazinecarboxamide BCTC and the urea SB-452533 (Figure 1).

[0038]

[0061] In preclinical models, tryptophan-based TRPM8 antagonists have been shown to reverse oxaliplatin-induced cold allodynia in C57 / BL6 mice. In this regard, the presently disclosed novel biphenylamide-based TRPM8 antagonists with high nanomolar potency and moderate TRPM8 selectivity were found to reverse cold allodynia in C57 / BL6 mice with chemotherapy-induced (oxaliplatin) chronic neuropathic pain (also known as chemotherapy-induced peripheral neuropathy or CIPN). Furthermore, the TRPM8 antagonists disclosed herein may also be useful in other pain conditions, such as cold and mechanical allodynia associated with chronic neuropathic pain. The conventional TRPM8 antagonists DFL23448 and DFL23693 significantly attenuate nociceptive responses in chronic constriction injury (CCI)-induced cold and mechanical allodynia models of neuropathic pain. Similarly, conventional TRPM8 antagonist PBMCs reduce CCI-induced cold allodynia in preclinical models. Consistent with these observations, TRPM8 - / -Mice do not exhibit increased cooling-induced sensitivity (cold allodynia) after CCI of the sciatic nerve; similarly, downregulation of TRPM8 in the L5 dorsal root ganglion (DRG) ipsilateral to CCI-induced nerve injury using a TRPM8 antisense oligonucleotide (intrathecally administered) results in attenuation of cold hyperalgesia. Without wishing to be bound by any particular theory or mechanism, it is believed that the TRPM8 antagonists described herein may alleviate thermal and mechanical allodynia in chronic neuropathic pain states, potentially providing a novel, non-opioid therapy for the treatment of chronic pain, and thus offering a new treatment for opioid addiction. In some embodiments of the present invention, TRPM8 is the target of the TRPM8 antagonists described herein for novel pain medications that control sensory responses to pain stimuli at the peripheral and / or CNS levels. In some embodiments, the TRPM8 antagonists described herein may also find utility in other disorders, such as cold hypersensitivity in inflammatory pain, orofacial pain, overactive bladder and painful bladder syndrome, disorders involving thermoregulation, including disorders in which induction of hypothermia or reduction of body temperature is beneficial (e.g., during cardiac arrest, neonatal encephalopathy, stroke, etc.), migraine, prostate cancer, oral squamous cell carcinoma, nicotine addictive behaviors, etc.

[0039]

[0062] The presently disclosed subject matter therefore includes TRPM8 antagonists and related methods. In particular, certain embodiments of the presently disclosed subject matter relate to TRPM8 antagonists and methods of using these antagonists for the treatment of pain.

[0040]

[0063] In some embodiments of the presently disclosed subject matter, the compound of formula (I) is: [ka] (wherein R1 is selected from cycloalkyl, bicycloalkyl, or tricycloalkyl groups, each of which has 4 to 12 carbon atoms and is optionally substituted with an alkyl group having 1 to 6 carbon atoms or a cycloalkyl group having 4 to 12 carbon atoms, each of which is optionally saturated or partially unsaturated), as shown below. [ka] is used herein to indicate the point of attachment for the various R1 groups.

[0041]

[0064] The term "cycloalkyl" is used generally to refer to a non-aromatic monocyclic ring system having from about 3 to about 12 carbon atoms, e.g., 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 carbon atoms, although in certain embodiments, such cycloalkyl groups further comprise an aromatic ring. Representative monocyclic cycloalkyl rings include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and the like.

[0042]

[0065] In some embodiments, such cycloalkyl groups can be combined to create polycyclic ring systems, such as "bicycloalkyl" groups, which in some embodiments contain two ring systems, or "tricycloalkyl" groups, which in other embodiments contain three ring systems. In some embodiments, such bicycloalkyl groups can be fused bicycloalkyl groups, in which two rings are directly linked to each other and share two adjacent atoms. In other embodiments, bicycloalkyl groups are bridged bicycloalkyl groups, in which two rings share three or more atoms, with two bridgehead atoms shared by the two rings and separated by a bridge containing at least one atom. In other embodiments, bicycloalkyl groups are spiro-linked bicycloalkyl groups, in which two rings are linked by a single atom.

[0043]

[0066] In some embodiments, the cycloalkyl groups described herein can be optionally saturated or partially unsaturated. The cycloalkyl group can be optionally substituted with an alkyl group, as defined herein, or another cycloalkyl group. In some embodiments, the cycloalkyl group is a branched cycloalkyl group in which the cycloalkyl group is attached to another chemical moiety, such as an alkyl group.

[0044]

[0067] With respect to the alkyl groups described herein and optionally substituted cycloalkyl, bicycloalkyl, or tricycloalkyl groups of the presently disclosed subject matter, the term "alkyl" is used herein to refer to C1-20 (inclusive) linear (i.e., "straight chain"), branched, saturated, or at least partially, and in some cases fully unsaturated (i.e., alkenyl and alkynyl) hydrocarbon chains, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, hexyl, octyl, ethenyl, propenyl, butenyl, pentenyl, hexenyl, octenyl, butadienyl, propynyl, methylpropynyl, butynyl, pentynyl, hexynyl, heptynyl, and allenyl groups. As used herein with respect to alkyl groups, "branched" typically refers to alkyl groups in which a lower alkyl group, such as methyl, ethyl, or propyl, is attached to a linear alkyl chain. "Lower alkyl" refers to an alkyl group having 1 to about 8 carbon atoms (i.e., C alkyl), e.g., 1, 2, 3, 4, 5, 6, 7, or 8 carbon atoms. "Higher alkyl," on the other hand, refers to an alkyl group having about 10 to about 20 carbon atoms, e.g., 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 carbon atoms. In certain embodiments, "alkyl" refers, specifically, to C straight-chain alkyl. In other embodiments, "alkyl" refers, specifically, to C branched-chain alkyl.

[0045]

[0068] In some embodiments of the presently disclosed subject matter, R1 is [ka] There is provided a compound of formula (I) above selected from the group consisting of: and analogs thereof.

[0046]

[0069] In some embodiments, R1 is [ka] and analogs thereof.

[0047]

[0070] In other embodiments, R1 is [ka] and analogs thereof.

[0048]

[0071] In a further embodiment, R1 is [ka] and analogs thereof.

[0049]

[0072] In some embodiments, R1 is [ka] and analogs thereof.

[0050]

[0073] In some embodiments, R1 is [ka] and analogs thereof.

[0051]

[0074] In yet further embodiments of formula (I) of the presently disclosed subject matter, R1 is [ka] is selected from the group consisting of:

[0052]

[0075] For example, in some embodiments, a compound of the following formula (II), also referred to herein as Compound 1: [ka] The present invention provides a TRPM8 antagonist having the following structure:

[0053]

[0076] As another example, in some embodiments, a compound of formula (III) below, also referred to herein as Compound 2: [ka] The present invention provides a TRPM8 antagonist having the following structure:

[0054]

[0077] As another example, in some embodiments, a compound of formula (IV), also referred to herein as Compound 3: [ka] The present invention provides a TRPM8 antagonist having the following structure:

[0055]

[0078] As another example, in some embodiments, a compound of formula (V), also referred to herein as compound 4: [ka] The present invention provides a TRPM8 antagonist having the following structure:

[0056]

[0079] As another example, in some embodiments, the compound of formula (VI), also referred to herein as compound 5: [ka] The present invention provides a TRPM8 antagonist having the following structure:

[0057]

[0080] As another example, in some embodiments, a compound of formula (VII), also referred to herein as compound 6: [ka] The present invention provides a TRPM8 antagonist having the following structure:

[0058]

[0081] As another example, in some embodiments, a compound of formula (VIII) below, also referred to herein as compound 7: [ka] The present invention provides a TRPM8 antagonist having the following structure:

[0059]

[0082] As another example, in some embodiments, the compound of formula (IX) below, also referred to herein as compound 8: [ka] The present invention provides a TRPM8 antagonist having the following structure:

[0060]

[0083] As another example, in some embodiments, the compound of formula (X) below, also referred to herein as compound 9: [ka] The present invention provides a TRPM8 antagonist having the following structure:

[0061]

[0084] As another example, in some embodiments, compounds of the following formula (XI), also referred to herein as Compound 10 or 12: [ka] The present invention provides a TRPM8 antagonist having the following structure:

[0062]

[0085] In some embodiments, the TRPM8 antagonist having formula (XI) above can be provided in several isomeric forms, including, but not limited to, the following: [ka]

[0063]

[0086] As another example, in some embodiments, a compound of formula (XII) below, also referred to herein as compound 11: [ka] The present invention provides a TRPM8 antagonist having the following structure:

[0064]

[0087] As another example, in some embodiments, a compound of formula (XIII) below, also referred to herein as compound 15: [ka] The present invention provides a TRPM8 antagonist having the following structure:

[0065]

[0088] As another example, in some embodiments, the compound of formula (XIV), also referred to herein as compound 13: [ka] The present invention provides a TRPM8 antagonist having the following structure:

[0066]

[0089] As another example, in some embodiments, the compound of formula (XV), also referred to herein as compound 14: [ka] The present invention provides a TRPM8 antagonist having the following structure:

[0067]

[0090] Additionally, in some embodiments of the presently disclosed subject matter, pharmaceutical compositions are provided that include a TRPM8 antagonist described herein and a pharmaceutically acceptable vehicle, carrier, or excipient. Indeed, when referring to certain embodiments herein, the terms "TRPM8 antagonist" and / or "compound" may or may not be used to refer to a pharmaceutical composition that includes a TRPM8 antagonist.

[0068]

[0091] As used herein, the term "pharmaceutically acceptable carrier" refers to sterile aqueous or non-aqueous solutions, dispersions, suspensions, or emulsions, as well as sterile powders for reconstitution into sterile injectable solutions or dispersions immediately prior to use. Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, to maintain the required particle size in the case of dispersions, and by the use of surfactants. These compositions may also contain adjuvants, such as preservatives, wetting agents, emulsifying agents, and dispersing agents. Prevention of microbial activity can be ensured by the inclusion of various antibacterial and antifungal agents, such as parabens, chlorobutanol, phenol, sorbic acid, and the like. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and the like.

[0069]

[0092] Prolonged absorption of injectable pharmaceutical forms can be achieved by including agents, such as aluminum monostearate and gelatin, which delay absorption. Injectable depot forms are made by forming microencapsule matrices of the drug in biodegradable polymers, such as polylactide-polyglycolide, poly(orthoesters) and poly(anhydrides). The rate of compound release can be controlled depending on the ratio of compound to biodegradable polymer and the properties of the particular biodegradable polymer used. Depot injectable formulations can also be prepared by entrapping the compound in liposomes or microemulsions that are compatible with body tissues. Injectable formulations can be sterilized, for example, by filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions that can be dissolved or dispersed in sterile water or other injectable sterile medium immediately before use. Suitable inert carriers include sugars, such as lactose.

[0070]

[0093] Suitable formulations may further include aqueous and non-aqueous sterile injectable solutions which may contain antioxidants, buffers, bacteriostats, bactericidal antibiotics and solutes which render the formulation isotonic with the body fluids of the intended recipient, as well as aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents.

[0071]

[0094] The compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles and may contain formulatory agents such as suspending, stabilizing, and / or dispersing agents. Alternatively, the compounds may be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.

[0072]

[0095] The formulations may be presented in unit-dose or multi-dose containers, for example, sealed ampoules and vials and may be stored in a frozen or freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier immediately prior to use.

[0073]

[0096] For oral administration, the compositions may take the form of, for example, tablets or capsules prepared by conventional techniques with pharmaceutically acceptable excipients such as binders (e.g., pregelatinized maize starch, polyvinylpyrrolidone, or hydroxypropylmethylcellulose), fillers (e.g., lactose, microcrystalline cellulose, or calcium hydrogen phosphate), lubricants (e.g., magnesium stearate, talc, or silica), disintegrants (e.g., potato starch or sodium starch glycolate), or wetting agents (e.g., sodium lauryl sulfate). Tablets may be coated by methods known in the art.

[0074]

[0097] Liquid preparations for oral administration can take the form of, for example, solutions, syrups, or suspensions, or can be a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations can be prepared by conventional techniques using pharmaceutically acceptable additives, such as suspending agents (e.g., sorbitol syrup, cellulose derivatives, or hydrogenated edible fats), emulsifying agents (e.g., lecithin or acacia), non-aqueous vehicles (e.g., almond oil, oily esters, ethyl alcohol, or fractionated vegetable oils), and preservatives (e.g., methyl or propyl-p-hydroxybenzoate or sorbic acid). Preparations can also contain buffer salts, flavoring agents, coloring agents, and sweetening agents, as appropriate. Preparations for oral administration can be suitably formulated to give controlled release of the active compound. For buccal administration, the compositions can take the form of tablets or lozenges formulated in a conventional manner.

[0075]

[0098] The composition can also be formulated as a preparation for implantation or injection.Thus, for example, the compound can be formulated with suitable polymeric or hydrophobic materials (e.g., as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives (e.g., a sparingly soluble salt).The compound can also be formulated in rectal compositions, creams or lotions, or transdermal patches.

[0076]

[0099] In some embodiments of the presently disclosed subject matter, methods for treating pain using the TRPM8 antagonists described herein are further provided. As used herein, the term "treatment" or "treating" refers to any treatment of a condition of interest (e.g., pain), including, but not limited to, preventive and therapeutic treatment. Thus, the term "treatment" or "treating" includes, but is not limited to, reducing the onset of a condition of interest or the progression of a condition of interest, inhibiting the progression of a condition of interest, halting or reducing the further progression of a condition of interest, reducing the severity of a condition of interest, improving or alleviating symptoms associated with a condition of interest, and causing regression of a condition of interest or one or more symptoms associated with a condition of interest.

[0077]

[0100] The term "pain" is used herein to generally describe physical pain or discomfort caused by disease or injury, typically conveyed by sensory neurons to a subject's brain to signal actual or potential damage to the body. Such pain can arise from any number of conditions, including injury and disease, but can also result from psychological conditions, such as depression, or may have no discernible trigger. Pain includes both acute and chronic pain. Acute pain can result from tissue damage, such as skin burns, broken bones, headaches, and muscle spasms, and usually subsides once the injury heals or the source of the pain (stimulus) is removed. Chronic pain, on the other hand, persists or progresses over a long period of time and is often resistant to medical treatment. Such chronic pain is often caused by several different medical conditions, including, but not limited to, diabetes, arthritis, migraines, fibromyalgia, cancer, shingles, sciatica, and previous trauma or injury, and can worsen in response to environmental and / or psychological factors. Other types of chronic pain include allodynia, hyperalgesia, and phantom limb pain, as well as other types of long-lasting pain caused by or exacerbated by at least some damage to the nervous system (i.e., neuropathic pain). In some embodiments of the methods described herein, the pain treated by the TRPM8 antagonists described herein is chronic neuropathic pain. In some embodiments, the pain treated is chemotherapy-induced neuropathic pain, cold allodynia in chronic neuropathic pain, mechanical allodynia in chronic neuropathic pain, cold hypersensitivity in inflammatory pain and nerve injury, orofacial pain, cold-induced pain, migraine, or painful bladder syndrome.

[0078]

[0101] In some embodiments, each of the above types of pain, including the severity of such types of pain, can be assessed by methods known to those skilled in the art. For example, in some embodiments, standard clinical measures of pain used to assess chemotherapy (e.g., oxiplatin)-induced peripheral neuropathy include the cylinder test, FACT / GOG-NTX-13 or FACT / GOG-NTX-4 (neurotoxicity subscale), and the BPI-SF mean pain severity item. In some embodiments, standard clinical measures of neuropathic pain include the cold pain test, measuring the change in mean pain intensity, measuring the change from baseline in pain intensity score over a specific period of time, measuring the change from baseline in weekly average daily pain ratings, measuring the change in mean daily pain intensity score, measuring the reduction in pain intensity after bunionectomy, measuring mean daily pain intensity, and / or using a numeric rating scale or pain numerical rating scale (NRS or NPRS).

[0079]

[0102] For administration of the therapeutic compositions (e.g., TRPM8 antagonists) described herein, conventional methods for estimating human dosages based on doses administered in mouse animal models can be performed using a conversion factor to convert mouse doses to human doses: human dose per kg = mouse dose per kg / 12 (Freireich et al., (1966) Cancer Chemother Rep. 50:219-244). Doses can also be expressed as milligrams per square meter of body surface area, because this method correlates better with certain metabolic and excretory functions than body weight. Furthermore, body surface area can be used as a common denominator for drug dosages in adults and children, as well as in different animal species, as described by Freireich et al. (Freireich et al., (1966) Cancer Chemother Rep. 50:219-244). Briefly, to express a mg / kg dose in any species as an equivalent mg / sq-m dose, the dose is multiplied by the appropriate km factor. For an adult human, 100 mg / kg is 100 mg / kg x 37 kg / sq-m = 3700 mg / m2 is equal to.

[0080]

[0103] Suitable methods for administering therapeutic compositions according to the methods of the presently disclosed subject matter include, but are not limited to, systemic administration, parenteral administration (including intravascular, intramuscular, and / or intraarterial administration), oral delivery, buccal delivery, rectal delivery, subcutaneous administration, intraperitoneal administration, intrathecal administration, intraventricular administration, inhalation, intratracheal placement, surgical implantation, transdermal delivery, local injection, intranasal delivery, and ultrafast injection / impulse. Where appropriate, continuous infusion can enhance drug accumulation at the target site (see, e.g., U.S. Patent No. 6,180,082).

[0081]

[0104] Regardless of the route of administration, the compositions of the presently disclosed subject matter are typically administered in an amount effective to achieve the desired response. Thus, the term "effective amount" is used herein to refer to the amount of a therapeutic composition (e.g., a TRPM8 antagonist and a pharmaceutically acceptable vehicle, carrier, or excipient) sufficient to produce a measurable biological response (e.g., a reduction in pain). The actual dosage level of the active ingredient in the therapeutic composition of the presently disclosed subject matter can be varied to administer an amount of the active compound effective to achieve the desired therapeutic response for a particular subject and / or application. Of course, the effective amount in any particular case will depend on a variety of factors, including the activity of the therapeutic composition, formulation, route of administration, combination with other drugs or treatments, the severity of the condition being treated, and the physical condition and prior medical history of the subject being treated. Preferably, the lowest dose is administered, and the dose is titrated up to the lowest effective amount in the absence of dose-limiting toxicity. Determination and adjustment of a therapeutically effective amount, as well as evaluation of when and how to make such adjustments, are known to those skilled in the art.

[0082]

[0105] For further guidance on formulations and dosages, see U.S. Pat. Nos. 5,326,902, 5,234,933, International Patent Application Publication No. WO 93 / 25521, Berkow et al. (1997) The Merck Manual of Medical Information, Home Edition, Merck Research Laboratories, Whitehouse Station, New Jersey; Goodman et al. (1996) Goodman & Gilman's the Pharmacological Basis of Therapeutics, 9th Edition, McGraw-Hill Health Professions Division, New York; Ebadi, (1998) CRC Desk Reference of Clinical Pharmacology, CRC Press, Boca Raton, Florida; Katzung, (2001) Basic & Clinical Pharmacology, 8th Edition, Lange Medical Books / McGraw-Hill Medical Pub. Division, New York; Remington et al. (1975) Remington's Pharmaceutical Sciences, 15th ed., Mack Pub. Co., Easton, Pennsylvania; and Speight et al. (1997) Avery's Drug Treatment: A Guide to the Properties, Choice, Therapeutic Use and Economic Value of Drugs in Disease Management, 4th ed., Adis International, Auckland / Philadelphia; Duch et al. (1998) Toxicol. Lett. 100-101:255-263.

[0083]

[0106] As used herein, the term "subject" includes both human and animal subjects. Thus, veterinary therapeutic uses are provided by the presently disclosed subject matter. Thus, the presently disclosed subject matter provides for the treatment of mammals, such as humans, as well as endangered and therefore important mammals, such as Siberian tigers; economically important animals, such as animals raised for human consumption; and / or socially important animals to humans, such as animals kept as pets or in zoos. Examples of such animals include, but are not limited to, carnivores, such as cats and dogs; swine, such as pigs, hogs, and wild boars; ruminants and / or ungulates, such as cattle, oxen, sheep, giraffes, deer, goats, bison, and camels; and horses. Treatment of birds is also provided, including treatment of endangered and / or zoo-held bird species, as well as fowl, more particularly domestic fowl, i.e., poultry such as turkeys, chickens, ducks, geese, guinea fowl, etc., because of their economic importance to humans. Thus, treatment of livestock is also provided, including, but not limited to, domestic swine, ruminants, ungulates, horses (including sport horses), poultry, etc.

[0084]

[0107] The presently disclosed subject matter is further illustrated by the following specific, but non-limiting examples. [Example]

[0085]

[0108] Materials and Methods

[0109] Molecular Modeling

[0110] Homology modeling of hTRPM8. The human TRPM8 model is based on the cryo-EM structure of the white-collared flycatcher (Ficedula albicollis) (TRPM8 FA , PDB:6BPQ, resolution: approximately 4.1 Å), and hTRPM8 is TRPM8 FAIt shares 83% sequence identity with hTRPM8. The cryo-EM structure was downloaded from the Protein Data Bank. All residues were repaired and energy minimized using SYBYL-X1.3. The full-length sequence of hTRPM8 (Q7Z2W7, 1104 residues) was obtained from UniProtKB / Swiss-Prot. Sequence alignment and homology modeling were performed using previously reported protocols.

[0086]

[0111] The hTRPM8 model was constructed using Modeller 9.18. Once the 3D model was generated, it was energy minimized using SYBYL-X 1.3. Briefly, the parameters defined in SYBYL were as follows: gradient was set to 0.5 kcal / mol, maximum iterations was set to 5000, force field was set to MMFF94s, and charge was set to MMFF94. All these settings were the same as those previously described. The overall quality of the 3D model was then confirmed using proSA-web Z-score and PROCHECK Ramachandran plot.

[0087]

[0112] Molecular docking of hTRPM8 to ligands. The docking program Surflex-Dock GeomX (SFXC) implemented in SYBYL-X 1.3 was used to construct the TRPM8-ligand complex, where the overall score was calculated as -log 10 (K d) were then fitted in SYBYL-X1.3 with the MOLCAD module to explore the potential binding pocket of hTRPM8, which included the following residues: Phe738 (S1), Tyr745 (S1), Glu782 (S2), Glu785 (S2), Trp798 (S3), Asn799 (S3), Asp802 (S3), Ala805 (S3), Arg842 (S4), His845 (S4), Ile846 (S4), Val849 (S4), Glu1004 (TRP helix), Tyr1005 (TRP helix), Arg1008 (TRP helix), and Leu1009 (TRP helix). All parameters and molecular docking protocols can be found in a previous report.

[0088]

[0113] Molecular Dynamics (MD) Simulations. To accelerate MD simulations, the transmembrane domain of hTRPM8 (residues Gln671 to Asn1010) was selected to simulate TRPM8 with different ligands. Each monomer of the TRPM8 receptor was complexed with one ligand, so there were four (identical) ligands for each simulation. The system was then complexed with 514 l-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) lipids, 51470 water molecules, and 156 Cl molecules. - and 140 Na + The TRPM8 molecules were solvated in a 0.15 mol / L NaCl solution containing ions. The initial conformations of TRPM8 and the ligand were obtained from molecular docking studies. The initial simulation box size was set to approximately 151 Å x 151 Å x 119 Å. The AMBER ff14SB force field was applied to TRPM8, and the AMBER Lipid14 force field was applied to the lipid. Water molecules were treated using the TIP3P water model.

[0089]

[0114] All MD simulations were then performed using the PMEMD.mpi and PMEMD.cuda modules in the AMBER16 package. To avoid possible steric clashes, several minimization steps were performed for each system. Each system was then gradually heated from 0 to 300 K in a heating step, followed by an equilibration and generation step (300 K) with a time step of 2 fs. Periodic boundary conditions were employed to maintain constant temperature and pressure (NPT) constancy. The pressure was set to 1 atm, and anisotropic (x) was obtained with a pressure relaxation time of 1 ps. - , y - , z - ) pressure scaling protocol. Temperature was controlled at 2 ps -1 The systems were kept constrained by Langevin dynamics with a collision frequency of . Long-range electrostatics were treated by the Particle Mesh Ewald (PME) method, and the cutoff value for real-space interactions was set to 10 Å. All covalent bonds involving hydrogen atoms were constrained by the SHAKE algorithm. Each system was subjected to 100 ns MD simulations, and the trajectories of each simulated system were saved every 100 ps.

[0090]

[0115] Molecular mechanics / generalized born surface area (MM / GBSA) calculations. For the saved trajectories of each MD simulation, the MM / GBSA method was applied to calculate the binding energy of TRPM8 under different ligand treatments. To calculate the average binding energy, 50 snapshots were extracted from each trajectory every 200 ps from 90 to 100 ns using the following formula: ΔE bind = ΔE MM +ΔE SOL = ΔE MM +ΔE GB +ΔE SA Here, ΔE bind is the binding energy, and ΔE MMrepresents the total molecular mechanical energy in vacuum, which can be further divided into contributions from electrostatic, van der Waals forces, and internal energy. This term can be calculated computationally using molecular mechanical methods. ΔE SOL is the polar solvation energy (ΔE GB ) and the non-polar portion (ΔE SA ) and solvation energy. Furthermore, the energy of each residue was decomposed into main-chain and side-chain atoms. Energy decomposition allowed us to analyze the contribution of key residues to biological activity.

[0091]

[0116] Chemistry. Thin-layer chromatography was performed on Analtech silica gel GF 250 micron TLC plates. Plates were visualized with 254 nM UV light and staining with iodine. Flash chromatography was performed on F60 silica gel, 230-400 mesh, 60 Å (Silicycle® SiliaFlash®). Automated flash chromatography was performed on a Biotage Isolera Prime automated flash purification system with a multi-wavelength (200-400 nm) detector (model ISO-PSV) using Biotage SNAP Ultra cartridges (10 g or 25 g) packed with Biotage HP-Sphere™ 25-micron spherical silica at a flow rate of 12 or 25 mL / min using a binary gradient of solvent A (dichloromethane) / solvent B (diethyl ether) (99 / 1 to 94 / 6 for 2, 100 / 0 to 96:4 for 4, 100 / 0 to 98 / 2 for 5, 6, 9, 10, 12, 14, and 15, 96 / 4 to 94 / 6 for 7, and 100 / 0 to 94 / 6 for 13). Elution peaks were monitored at 254 and 280 nm. NMR was recorded on a Bruker Ascent 400 MHz NMR spectrometer using CDCl3. Mass spectrometry spectra were obtained on Agilent 1290 Infinity and 6490 Triple Quad LC / MS using electrospray ionization (ESI) mode. LC-UV-MS of compound 2 and its isomers (2A, 2B, and 2C) and compounds 10 and 12 was performed using an Accela UHPLC system (Thermo Scientific, San Jose, CA, USA) including an Accela 1250 pump, an open autosampler, and a PDA detector, followed by a Thermo Q Exactive Orbitrap mass spectrometer.Chromatographic separation was performed on an Agilent Eclipse XDB C18 column (1.8 μm particles and dimensions 2.1 mm × 100 mm with a 2.1 mm × 5 mm guard column) using a mobile phase consisting of A: 0.1% formic acid (v / v) in LC-MS-grade water and B: 0.1% formic acid (v / v) in acetonitrile, and two different elution methods. A gradient elution method was used for compound 2 and its isomers (2A, 2B, and 2C), consisting of 0% B to 95% B in 8 min, followed by a total column wash and equilibration period of 20 min. An isocratic elution method was used for compounds 10 and 12, which was 58% B held constant for 20 min. For both chromatographic methods, the flow rate was 300 μl / min, and 5 μl of sample was injected. UV detection was achieved using a PDA detector over the range of 200 to 600 nm, with specific channel wavelengths monitored (280 nm, 254 nm, and 214 nm). Mass spectrometer parameters consisted of electrospray ionization in positive ion mode, full MS mode with a 3.7 kV electrospray voltage, a resolution setting of 70,000, an AGC target of 1e6, a maximum IT of 100 ms, and a scan range of m / z 150–1000. Data processing was performed in Thermo Xcalibur version 4.1.31.9 using Qual Browser. Elemental analysis was performed by Atlantic Microlabs, Norcross, GA. The purity of all final compounds was greater than 99.6%.

[0092]

[0117] General amidation procedure. To a stirring solution of [1,1'-biphenyl]-4-carboxylic acid (1.00–1.5 equiv.) in THF (0.1 M) was added EDCI (1.04–1.56 equiv.), HOBt (1.04–1.56 equiv.), and EtN (1.2–3.3 equiv.), and the reaction was stirred at room temperature for 1 h. To this mixture was added a solution of a substituted amine (1.0–1.2 equiv.) in THF, and the reaction was stirred at 40 °C for 2–3 h or at room temperature for 1–3 days. The reaction was diluted with EtOAc and HO. The combined organic layers were washed with saturated NaCl (aq.), dried over NaSO, filtered, and concentrated.

[0093]

[0118] N-(2-Isopropyl-5-methylcyclohexyl)-[1,1'-biphenyl]-4-carboxamide (compound 2, a mixture of three isomers present in a ratio of 30:21:49 by LCMS). Prepared according to the general procedure using 5-methyl-2-(propan-2-yl)cyclohexan-1-amine (62 mg, 0.40 mmol). The crude residue was purified by flash chromatography using hexane / diethyl ether / NH4OH (100 / 0 / 0 to 95 / 5 / 0.5) followed by automated flash chromatography to give 83 mg of the title material in 62% yield. 1H NMR (Mixture) (400 MHz, CDCl3) δ 7.87-7.78 (m, 6H), 7.69-7.63 (m, 7H), 7.63-7.58 (m, 6H), 7.51-7.35 (m, 8H), 6.22 (d, J = 9.0 Hz, 2H), 6.16 (d, J = 8.4 Hz, 1H), 5.82 (d, J = 9.5 Hz, 1H), 4.63 4.55 (m, 2H), 4.39 (tt, J = 7.8, 3.9 Hz, 1H), 4.03 (qd, J = 10.9, 3.9 Hz, 1H), 2.15-2.07 (m, 1H), 2.06–1.91 (m, 4H), 1.90–1.60 (m, 4H), 1.56–1.23 (m, 3H), 1.22–1.11 (m, 6H), 1.09–0.82 (m, 27H). MS (ESI) (mixture) m / z 336.30 (M+H) + LCMS (mixture), RT (Pick 1) = 8.76 min, m / z (M+H) + = 336.2; LCMS R T (ピーク2) = 8.84 min, m / z (M+H) + = 336.2; LCMS R T (ピーク3) = 9.05 min, m / z (M+H) + = 336.2. C 23 H 29 NO (Mixture) Analytical calculated value: C, 82.34; H, 8.71; N, 4.18; Found value: C, 82.07; H, 8.58; N, 4.29.

[0094]

[0119] Separation of the isomers of compound 2 (50 mg) was carried out by preparative thin-layer chromatography (TLC) (2000 microns, 20 × 20 cm, Analtech) using hexane:EtOAc:NHOH (79.6:20.0:0.4). The plate was exposed twice to the above solvent system to give isomer 2A (15 mg) and a mixture of isomers 2B and 2C (33 mg). Further preparative TLC of the mixture of isomers 2B and 2C was carried out using a gradient of hexane:EtOAc:NHOH (89.6:9.9:0.5 → 84.6 / 14.9 / 0.5) to give isomer 2B (2.3 mg) and isomers 2B and 2C (16.6 mg).

[0095]

[0120] Isomer 2A, isolated: 1 H NMR (400 MHz, CDCl3) δ7.86-7.84 (m, 2H), 7.70-7.67 (m, 2H), 7.65-7.62 (m, 2H), 7.51-7.48 (m, 2H), 7.44-7.39 (m, 1H), 6.24 (d, J = 8 Hz, 1H), 4.64-4.59 (m, 1H), 2.08-2.03 (m, 1H), 1.99-1.95 (m, 1H), 1.85-1.81 (m, 1H), 1.54 (br s, 1H), 1.48-1.41 (m, 1H), 1.28 (s, 1H), 1.22-1.04 (m, 3H), 1.00-0.92 (m, 9H).LCMS R T = 9.26 min, m / z (M+H) + = 336.2. TLC (SiO2) R f 0.37 (8:2 hexane:diethyl ether + 2 drops of NH4OH).

[0096]

[0121] Isomer 2B, isolated: 1H NMR (400 MHz, CDCl3) δ7.85-7.82 (m, 2H), 7.67-7.60 (m, 4H), 7.49-7.36 (m, 3H), 5.79 (d, J = 8 Hz, 1H), 4.03 (qd, J = 10.9, 3.8 Hz, LCMS RT = 8.85 min, m / z (M+H) + = 336.2. TLC (SiO2) R f 0.31 (8:2 hexane:diethyl ether + 2 drops of NH4OH).

[0097]

[0122] Isomer 2C (obtained as 2B:2C in a 70:30 ratio): 1 H NMR (400 MHz, CDCl3) δ7.87-7.83 (m, 2H), 7.69-7.67 (m, 2H), 7.64-7.62 (m, 2H), 7.51-7.47 (m, 2H), 7.43-7.39 (m, 1H), 6.18 (2C, d, J = 8 Hz, 0.5H), 5.84 (2B, J = 12 Hz, 1H), 4.39 (2C, tt, J = 7.8, 3.9 Hz, 1H), 4.05 (2B, qd, J = 10.9, 3.8 Hz, 1H), 2.16-2.12 (m, 1H), 2.05-1.99 (m, 1H), 1.89 (br s, 1H), 1.81-1.61 (m, 4H), 1.57-1.54 (m, 1H), 1.48-1.15 (m, 4H), 1.06-0.98 (2C, m, 4H), 0.96-0.88 (2B, m, 9H). LCMS RT (isomer B) = 8.93 min, m / z (M+H) + = 336.2. LCMS R T (isomer C) = 9.00 min, m / z (M+H) += 336.2. TLC (isomer C) (SiO2) R f 0.28 (8:2 hexane:diethyl ether + 2 drops of NH4OH).

[0098]

[0123] N-Cyclohexyl-[1,1'-biphenyl]-4-carboxamide (Compound 3). Prepared according to the general procedure using cyclohexylamine HCl (342 mg, 2.52 mmol). The crude residue was purified by trituration with 30 mL hexane / ether (90 / 10) followed by trituration with 15 mL MeOH to give 536 mg of the title material in 76% yield. 1 H NMR (400 MHz, CDCl3) δ7.86-7.79 (m, 2H), 7.68-7.57 (m, 4H), 7.51-7.42 (m, 2H), 7.42-7.34 (m, 1H), 6.00 (d, J = 8.1 Hz, 1H), 4.01 (dddd, J = 14.7, 10.7, 8.0, 4.0 Hz, 1H), 2.07-2.04 (m, 2H), 1.77 (dt, J = 13.7, 3.7 Hz, 2H), 1.67 (dt, J = 12.7, 3.7 Hz, 1H), 1.52-1.37 (m, 2H), 1.33-1.14 (m, 3H). MS (ESI) m / z 280.3 (M+H) + .C 19 H 21 Analytical values ​​calculated for NO.0.3H2O: C, 80.13; H, 7.65; N, 4.92; Found: C, 80.15; H, 7.37; N, 4.99.

[0099]

[0124] N-(bicyclo[2.2.1]heptan-2-yl)-[1,1'-biphenyl]-4-carboxamide (compound 4, single isomer). Prepared according to the general procedure using bicyclo[2.2.1]heptan-2-amine HCl (106 mg, 0.72 mmol). The crude residue was purified by automated flash chromatography to give 80 mg of the title material in 38% yield. 1H NMR (400 MHz, CDCl3) δ7.88-7.77 (m, 2H), 7.69-7.58 (m, 4H), 7.51-7.42 (m, 2H), 7.47-7.34 (m, 1H), 6.17 (d, J = 7.2 Hz, 1H), 4.35 (dddd, J = 11.3, 6.8, 4.4, 1.6 Hz, 1H), 2.59 (br s, 1H), 2.39-2.14 (m, 2H), 1.71-1.44 (m, 2H), 1.39 (ddt, J = 9.9, 3.2, 1.7 Hz, 1H), 1.34-1.23 (m, 1H), 0.86 (ddd, J = 12.9, 4.7, 3.0 Hz, 1H). MS (ESI) m / z 292.4 (M+H) + .C 20 H 21 Analytical calculated values ​​for NO: C, 82.44; H, 7.26; N, 4.81; Found values: C, 82.05; H, 7.10; N, 4.84.

[0100]

[0125] N-Cycloheptyl-[1,1'-biphenyl]-4-carboxamide (Compound 5). Prepared according to the general procedure using cycloheptylamine (100 mg, 0.88 mmol). The crude residue was purified by automated flash chromatography to give 200 mg of the title material in 77% yield. 1 H NMR (400 MHz, CDCl3) δ7.86-7.78 (m, 2H), 7.69-7.57 (m, 4H), 7.50-7.43 (m, 2H), 7.42-7.35 (m, 1H), 6.07 (d, J = 8.1 Hz, 1H), 4.18 (ddt, J = 12.8, 8.4, 3.6 Hz, 1H), 2.17-1.98 (m, 3H), 1.73-1.60 (m, 4H), 1.58-1.49 (m, 5H). MS (ESI) m / z 294.3 (M+H) + .C 20 H 23Analytical calculated values ​​for NO: C, 81.87; H, 7.90; N, 4.77; Found values: C, 81.84; H, 7.76; N, 4.67.

[0101]

[0126] N-(bicyclo[3.2.1]octan-3-yl)-[1,1'-biphenyl]-4-carboxamide (compound 6). Prepared according to the general procedure using bicyclo[3.2.1]octan-3-amine HCl (90 mg, 0.55 mmol). The crude residue was purified by automated flash chromatography to give 54 mg of the title material in 32% yield. 1 H NMR (400 MHz, CDCl3) δ7.84-7.77 (m, 2H), 7.70-7.56 (m, 4H), 7.51-7.42 (m, 2H), 7.42-7.34 (m, 1H), 5.86 (d, J = 8.4 Hz, 1H), 4.33 (tdt, J = 11.5, 8.4, 5.8 Hz, 1H), 2.31 (br s, 2H), 2.06-1.97 (m, 2H), 1.69 (br s, 4H), 1.54-1.44 (m, 1H), 1.40 (d, J = 11.2 Hz, 1H), 1.33-1.23 (m, 2H).MS (ESI) m / z 306.3 (M+H) + .C 21 H 23 Analytical calculated values ​​for NO: C, 82.58; H, 7.59; N, 4.59; Found values: C, 82.35; H, 7.68; N, 4.58.

[0102]

[0127] N-Cyclooctyl-[1,1'-biphenyl]-4-carboxamide (Compound 7). Prepared according to the general procedure using cyclooctylamine (500 mg, 3.93 mmol). The crude residue was purified by flash chromatography using hexane / EtOAc (95 / 5 to 30 / 70) followed by automated flash chromatography to give 605 mg of the title material in 50% yield. 1H NMR (400 MHz, CDCl3) δ7.86-7.78 (m, 2H), 7.68-7.56 (m, 4H), 7.51-7.42 (m, 2H), 7.42-7.34 (m, 1H), 6.08 (d, J = 8.1 Hz, 1H), 4.23 (ddq, J = 12.0, 8.0, 3.7 Hz, 1H), 2.01-1.89 (m, 2H), 1.78-1.60 (m, 12H). MS (ESI) m / z 308.3 (M+H) + .C 21 H 25 Analytical calculated values ​​for NO: C, 82.04; H, 8.20; N, 4.56; Found values: C, 81.93; H, 8.10; N, 4.58.

[0103]

[0128] N-(Decahydronaphthalen-1-yl)-[1,1'-biphenyl]-4-carboxamide (compound 8, mixture of three isomers). Prepared according to the general procedure using decahydronaphthalen-1-amine HCl (91 mg, 0.483 mmol). The crude residue was purified by trituration with 15 mL MeOH to give 136 mg of the title material in 84% yield. 1 H NMR (400 MHz, CDCl3) δ7.87-7.79 (m, 6H), 7.72-7.57 (m, 12H), 7.51-7.42 (m, 6H), 7.42-7.35 (m, 3H), 6.05 (d, J = 8.5 Hz, 1H), 5.82 (d, J = 9.3 Hz, 2H), 4.15 (ddt, J = 11.8, 7.9, 4.0 Hz, 1H), 3.89-3.75 (m, 2H), 2.16-2.06 (m, 3H), 1.97-0.81 (m, 45H). MS (ESI) m / z 334.30 (M+H) + .C 23 H 27 Analytical values ​​calculated for NO. 0.3 H2O: C, 81.52; H, 8.21; N, 4.13; Found values: C, 81.44; H, 7.94; N, 4.16.

[0104]

[0129] N-(1,2,3,4-tetrahydronaphthalen-1-yl)-[1,1'-biphenyl]-4-carboxamide (compound 9). Prepared according to the general procedure using 1,2,3,4-tetrahydro-1-naphthylamine (250 mg, 1.70 mmol). The crude residue was purified by automated flash chromatography to give 384 mg of the title material in 69% yield. 1 H NMR (400 MHz, CDCl3) δ7.90-7.82 (m, 2H), 7.69-7.57 (m, 4H), 7.51-7.43 (m, 2H), 7.42-7.34 (m, 2H), 7.24-7.12 (m, 3H), 6.37 (d, J = MS (ESI) m / z 328.20 (M+H) + .C 23 H 21 Analytical calculated values ​​for NO: C, 84.37; H, 6.46; N, 4.28; Found values: C, 84.14; H, 6.37; N, 4.17.

[0105]

[0130] N-(Decahydronaphthalen-2-yl)-[1,1'-biphenyl]-4-carboxamide (compound 10, a mixture of two isomers present in an 86:13 ratio by LCMS) and N-((2SR,9RS,10SR)-decahydronaphthalen-2-yl)-[1,1'-biphenyl]-4-carboxamide (compound 12, single isomer). Prepared according to the general procedure using decahydronaphthalen-2-amine (63 mg, 0.41 mmol). The crude residue was purified by automated flash chromatography to give 10 (111 mg, 80%) and 12 (28 mg, 20%). 1H NMR (mixture) (400 MHz, CDCl3, 10) δ7.87-7.78 (m, 3H), 7.69-7.57 (m, 6H), 7.50-7.42 (m, 3H), 7.42-7.35 (m, 1H), 6.00 (d, J = 8.1 Hz, 1H), 5.94 (d, J = 8.4 Hz, 0.31H), 4.20 (s, 0.26H), 4.00 (tdt, J = 11.9, 8.2, 4.2 Hz, 1H), 2.18-1.59 (m, 9H), 1.57-0.84 (m, 8H). MS (ESI) (Mixture) m / z 334.3 (M+H) + .LCMS (mixture) R T (Peak 1 (major isomer), corresponding to 12) = 7.91 min, m / z (M+H) + = 334.2; LCMS R T (Peak 2 (minor isomer)) = 8.70 min, m / z (M+H) + = 334.2. C 23 H 27 Analytical calculation for NO (mixture): C, 82.84; H, 8.16; N, 4.20; Found: C, 82.57; H, 7.97; N, 4.20. TLC (major isomer, corresponds to 12) (SiO2) R f 0.54 (8:2 hexane: EtOAc). TLC (minor isomer) (SiO2) R f 0.59 (8:2 hexane: EtOAc).

[0106]

[0131] 1H NMR (400 MHz, CDCl3, compound 12, single isomer) δ7.87-7.79 (m, 2H), 7.70-7.57 (m, 4H), 7.51-7.43 (m, 2H), 7.42-7.35 (m, 1H), 6.00 (d, J = 8.1 Hz, MS (ESI) (single isomer) m / z 334.3 (M+H) + . LCMS (single isomer) R T = 8.04 min, m / z (M+H) + = 334.2. C 23 H 27 Analysis calculated for NO (single isomer): C, 82.84; H, 8.16; N, 4.20; Found: C, 82.73; H, 8.13; N, 4.14. TLC (SiO2) R f 0.54 (8:2 hexane: EtOAc).

[0107]

[0132] Compound 12 1 H, 13 C, gCOSY, NOESY, gHSQCAD, gHMBCAD, gH2BC. All experiments were performed by 1 H and 13 The experiments were carried out on an Agilent DDR2 500 MHz spectrometer equipped with a One NMR probe operating at C resonance frequencies of 499.90 MHz and 125.71 MHz, respectively. Experiments were carried out at room temperature using CDCl as the solvent. 1 The H spectrum shows the residual protonated solvent (7.26 ppm). 13 C was referenced to 77 ppm. Spectra were processed using the MestReNova (12.0.3) NMR processing program.

[0108]

[0133] 1H NMR: 10 s wait time, 8013 Hz spectral window, 2.04 s acquisition time, 8 scans, baseline correction was applied using Whittaker smoother (autodetect).

[0109]

[0134] 13 C NMR: broadband 1 H-decoupling, 1 second wait time, 512 scans, 31250 Hz spectral window, 1.05 second acquisition time. Baseline correction was applied using a Whittaker smoother (autodetect), and exponential multiplication of 0.5 Hz was applied.

[0110]

[0135] gCOSY: 1 second latency, 4 scans per increment, 200 increments, 4882 Hz spectral window, 0.15 second acquisition time. F1 and F2 were Fourier transformed after multiplication by a sine squared II function (50%) as implemented by MestReNova. Linear prediction (Zhu-Bax) was applied to 1024 points in F1. Baseline correction was applied in both dimensions using a Whittaker smoother (autodetect).

[0111]

[0136] gH2BC: 1 second latency, 8 scans per increment, 200 increments, 8013, 25141 Hz spectral window (respectively 1 H and 13 C), 0.15 s acquisition time. F1 was multiplied by a Gaussian and F2 by a sine squared II function (50%) before Fourier transformation, as implemented by MestReNova. Baseline correction was applied in both dimensions using a Whittaker smoother (autodetect). Linear prediction (Zhu-Bax) was applied to 2048 points in F1.

[0112]

[0137] gHMBCAD: 1 s latency, 8 scans per increment, 320 increments; 8013, 30166 Hz spectral window (respectively 1 H and 13C), 0.15 s acquisition time. F2 was multiplied by a Gaussian and F1 by a sine squared II function (50%) before Fourier transformation, as performed by MestReNova. Baseline correction was applied in both dimensions using a Whittaker smoother (autodetect). Linear prediction (Zhu-Bax) was applied to 2048 points in F1.

[0113]

[0138] gHSQCAD: 1 second latency, 4 scans per increment, 200 increments; 8013, 25141 Hz spectral window (respectively 1 H and 13 C), 0.15 s acquisition time. F1 and F2 were Gaussian multiplied before Fourier transformation. Baseline correction was applied in both dimensions using a Whittaker smoother (autodetect). Linear prediction (Zhu-Bax) was applied to 2048 points in F1.

[0114]

[0139] N-(1,2,3,4-tetrahydronaphthalen-2-yl)-[1,1'-biphenyl]-4-carboxamide (compound 11). Prepared according to the general procedure using 1,2,3,4-tetrahydronaphthalen-2-amine HCl (197 mg, 1.34 mmol). The crude residue was purified by trituration with 15 mL MeOH to give 328 mg of the title material in 75% yield. 1 H NMR (400 MHz, CDCl3) δ7.95-7.93 (m, 2H), 7.77-7.71 (m, 4H), 7.57-7.50 (m, 3H), 7.37 (s, 1H), 7.23-7.26 (m, 3H), 6.29 (d, J = 4 Hz, 1H), 4.65 (br s, 1H), 3.39 (d, J = 20 Hz, 1H), 3.07 (br s, 1H), 2.88-2.94 (m, 1H), 2.33-2.30 (m, 1H), 2.09-2.00 (m, 1H), 1.70 (s, 1H). MS (ESI) m / z 328.2 (M+H) + .C 23 H 21Calculated values ​​for NO: C, 84.37; H, 6.46; N, 4.28; Found values: C, 84.10; H, 6.42; N, 4.25.

[0115]

[0140] N-(spiro[5.5]undecan-3-yl)-[1,1'-biphenyl]-4-carboxamide (compound 13). Prepared according to the general procedure using spiro[5.5]undecan-3-amine HCl (90 mg, 0.44 mmol). The crude residue was purified by automated flash chromatography to give 130 mg of the title material in 84% yield. 1 H NMR (400 MHz, CDCl3) δ7.86-7.79 (m, 2H), 7.69-7.57 (m, 4H), 7.51-7.43 (m, 2H), 7.42-7.35 (m, 1H), 6.02 (d, J = 8.1 Hz, 1H), 3.97 (dddd, J = 14.9, 10.7, 8.3, 4.2 Hz, 1H), 1.88 (ddd, J = 13.1, 6.2, 3.8 Hz, 3H), 1.67 (d, J = 13.6 Hz, 3H), 1.42 (br s, 8H), 1.25 (td, J = 12.7, 4.4 Hz, 4H). MS (ESI) m / z 348.4 (M+H) + .C 24 H 29 Analytical calculated values ​​for NO: C, 82.95; H, 8.41; N, 4.03; Found values: C, 82.99; H, 8.42; N, 3.99.

[0116]

[0141] N-(spiro[4.5]decan-8-yl)-[1,1'-biphenyl]-4-carboxamide (compound 14). Prepared according to the general procedure using spiro[4.5]decan-8-amine HCl (91 mg, 0.48 mmol). The crude residue was purified by automated flash chromatography to give 110 mg of the title material in 68% yield. 1H NMR (400 MHz, CDCl3) δ7.87-7.79 (m, 2H), 7.69-7.57 (m, 4H), 7.51-7.43 (m, 2H), 7.42-7.35 (m, 1H), 6.01 (d, J = 8.1 Hz, 1H), 4.05-3.93 (m, 1H), 2.00-1.91 (m, 2H), 1.67-1.60 (m, 3H), 1.58-1.31 (m, 11H). MS (ESI) m / z 334.3 (M+H) + .C 23 H 27 Analytical calculated values ​​for NO: C, 82.84; H, 8.16; N, 4.20; Found values: C, 82.57; H, 8.16; N, 4.22.

[0117]

[0142] N-(adamantan-1-yl)-[1,1'-biphenyl]-4-carboxamide (compound 15). Prepared according to the general procedure using 1-adamantanamine HCl (100 mg, 0.54 mmol). The crude residue was purified by automated flash chromatography to give 110 mg of the title material in 62% yield. 1 H NMR (400 MHz, CDCl3) δ7.83-7.75 (m, 2H), 7.67-7.57 (m, 4H), 7.51-7.42 (m, 2H), 7.42-7.34 (m, 1H), 5.84 (s, 1H), 2.15 (br s, 9H), 1.73 (br s, 6H). MS (ESI) m / z 332.3 (M+H) + .C 23 H 25 Analytical values ​​calculated for NO. 0.1H2O: C, 82.89; H, 7.62; N, 4.20; Found: C, 82.87; H, 7.47; N, 4.18.

[0118]

[0143] In vitro pharmacology

[0144] Ca 2+Evaluation of TRPM8 agonist and antagonist activity using Fura-2-based Ca imaging 2+ Icilin-induced Ca imaging 2+ The effect of synthetic compounds on signaling was assessed. HEK-293 cells stably expressing human TRPM8 (a gift from Prof. Thomas Voets, Laboratory of Ion Channels Research, KU Leuven, Belgium) were first loaded with Fura-2 AM for 45 min, followed by a further 40 min to allow the dye to deesterify. The cells were then incubated for 1 min at 4°C for 1 h. 2+ The cells were bathed in free HBSS buffer and incubated with the test compound for 5 min. Then, icilin (500 nM, from Tocris), a known TRPM8 agonist, was added to the bath solution. One minute after the addition of icilin, 2 mM Ca was added to the bath solution. 2+ was added to the bath solution.

[0119]

[0145] Ratio fluorescence images were acquired using a QIClick™ digital CCD camera (QImaging, BC, Canada) mounted on a Nikon Eclipse Ti-S microscope. Sequential excitation was at 355 nm (F 355 ) and 380 nm (F 380 The fluorescence was provided by a Dual OptoLED power supply (Cairn) alternating between 470 nm and 550 nm wavelength LEDs. Emitted fluorescence was collected at 510 nm (470 nm to 550 nm). 12-bit images were acquired every 5 seconds with a MetaFluor® (Molecular Devices, USA). Fluorescence at each time point was sampled at both 355 nm and 380 nm wavelengths, corrected for autofluorescence, and the 355 nm / 380 nm ratio (F 355 / F 380 ) is then calculated to give Ca 2+ The total Ca influx 2+ Imaging experiments were performed at room temperature (22 °C). For comparison, peak Ca values ​​for each compound were 2+ Responses were normalized to that of icilin (500 nM). RQ-00203078 was purchased from Tocris.

[0120]

[0146] To obtain a concentration-response profile of icilin, Fura-2-loaded HEK-293 cells stably expressing human TRPM8 in different Petri dishes were incubated with Ca. 2+ The cells were immersed in HBSS-free solution and first incubated with gradient concentrations of icilin (10 -9 From 10 -6 M). One minute after the addition of icilin, 2 mM Ca 2+ was added to the bath solution, and the resulting Ca 2+ Influx (as Fura-2 fluorescence ratio) was recorded. EC 50 was obtained from the corresponding concentration-response curve.

[0121]

[0147] To determine the antagonist activity of the designed compounds (e.g., Table 1 below), 2+ Free Hanks' balanced salt solution (Ca 2+ Cells bathed in Ca-free HBSS were first incubated with different concentrations of compounds 2 to 15 (1 nM, 3 nM, 10 nM, 30 nM, 100 nM, 300 nM, 1 μM, 3 μM, 10 μM, 30 μM, and 100 μM) for 3 min. Then, 500 nM icilin was added, and after another 1 min, Ca 2+ Free HBSS, 2 mM free Ca 2+ The resulting HBSS was replaced with HBSS containing Ca 2+ The signal was measured. The TRPM8 antagonist RQ-00203078 was used as a positive control and for comparison due to its high nanomolar potency (<10 nM) at hTRPM8 relative to other antagonists reported in the literature. Compounds with IC50 values ​​≤ 100 nM were considered to be Ca 2+ Its intrinsic (agonist) ability to induce influx was tested alone at a single concentration of 10 μM and compared with the effect of 500 nM icilin.

[0122]

[0148] TRPA1 and TRPV1 selectivity assay. Fluo-8 Ca 2+ Ca using dyes and fluorescence 2+Flux assays were performed on a FLIPR microscope at excitation wavelengths of 470–495 nm and emission wavelengths of 515–575 nm. TETRA A total of eight compounds were measured using a plate reader (Molecular Devices) and exhibited approximately IC values ​​for TRPM8 for both agonist (intrinsic) and antagonist activity. 90 and 10×IC 90 The 10-fold selectivity was demonstrated by testing at concentrations corresponding to the 10-fold selectivity of TRPA1 and TRPV1. A recombinant HEK293 cell line stably expressing human TRPA1 (Eurofins Cat #CYL3066) and human TRPV1 (Eurofins Cat #CYL3063) was used for the study. Cells were cultured and maintained in DMEM-F12 medium supplemented with 10% FBS, 1% non-essential amino acids, and 400 μg / ml Geneticin. Allyl isothiocyanate (AITC, Millipore Sigma) and capsaicin (Tocris) were used as reference agonists, and ruthenium red (Tocris) and capsazepine (Millipore Sigma) were used as reference antagonists for TRPA1 and TRPV1, respectively. For the experiments, cells were seeded into flat-bottom collagen-coated 384-well plates and incubated at 37°C and 5% CO2. After 24 hours of incubation, the medium was aspirated and Fluo-8 Ca was added. 2+ 40 μl of dye loading buffer (modified Hank's balanced salt solution (HBSS), HBSS supplemented to contain 20 mM HEPES and 2.5 mM probenecid at pH 7.4) containing 5 μg / ml dye was added to the cells in each well and incubated for 80 minutes at 30°C (5% CO2) in a humidified chamber before initiating the FLIPR Tetra protocol. Test compounds were first dissolved in DMSO to 300x the final assay concentration and then diluted to the final dilution in assay buffer (modified Hank's balanced salt solution (HBSS), HBSS supplemented to contain 20 mM HEPES at pH 7.4). For the agonist assay, test compounds, vehicle control, and reference agonist (E maxEC = 300 μM (AITC) and 3 μM (capsaicin)) were added to the assay plate for 180 seconds after establishing a fluorescence baseline. For antagonist assays, cells were preincubated with test compound or positive control (known antagonist) for 5 minutes at room temperature, followed by EC = 300 μM (AITC) and 3 μM (capsaicin) 80 Concentration of reference agonist (AITC EC 80 = 10 μM capsaicin EC 80 Agonist: E = 0.1 μM) was applied for 180 seconds after establishing a fluorescence baseline. max 25% activation when normalized to EC 80 25% inhibition when normalized to

[0123]

[0149] Whole-cell patch clamp electrophysiology

[0150] HEK-293 Cell Culture. Human embryonic kidney (HEK) 293 cells (ATCC CRL-1573) were cultured in growth medium containing 90% Dulbecco's modified Eagle's medium, 10% fetal bovine serum, 100 U mL-1 penicillin-streptomycin, and 2 mM L-glutamine (Gibco). Cells were grown in 35 mm polystyrene dishes (Falcon) at 37°C in the presence of 5% CO2. Cells were transiently transfected with human TRPM8 in the pIRES2 plasmid containing EGFP as a reporter. This plasmid expresses a bicistronic mRNA with an internal ribosome entry site (IRES) between the TRPM8 gene and the fluorescent protein reporter gene, ensuring that the reporter is not covalently fused to TRPM8. Transient transfections were performed in 35 mm dishes (Falcon) using Fugene 6 transfection reagent (Promega) and 0.5 μg of plasmid at a ratio of 3 μL of transfection reagent per μg of plasmid according to the manufacturer's protocol. HEK-293 cells were validated by polymorphic genetic marker testing (DNA Diagnostics Center Medical).

[0124]

[0151] Whole-cell patch-clamp electrophysiology. 48 hours after transfection, cells were released from the culture dish by brief exposure to 0.25% trypsin / EDTA (Gibco), resuspended in supplemented DuI DMEM, seeded onto glass coverslips, and allowed to recover for 1-2 hours at 37°C in 5% CO2. Cells exhibiting green fluorescence, indicating successful transfection, were selected for electrophysiological measurements. Cells were placed in a chamber containing an extracellular solution containing (in mM): NaCl 132, KCl 4.8, MgCl2 1.2, CaCl2 2, HEPES 10, and glucose 5, with the pH adjusted to 7.4 with NaOH and the osmolarity adjusted to 310 mOsm with sucrose. Pipettes were filled with a solution containing (in mM): K+ gluconate 135, KCl 5, MgCl2 1, EGTA 5, and HEPES 10, with the pH adjusted to 7.2 with KOH and the osmolarity adjusted to 300 mOsm with sucrose. Chemicals were obtained from Sigma-Aldrich. Osmolarity was measured using a Vapro 5600 vapor pressure osmometer (Wescor). Whole-cell voltage-clamp current measurements were performed using an Axopatch 200B amplifier (Axon Instruments) and pClamp 10.3 software (Axon Instruments). Data were acquired at 2 kHz and filtered at 1 kHz. Patch pipettes were pulled from borosilicate glass capillaries (World Precision Instruments) using a P-2000 laser puller (Sutter Instruments) and heat-polished using an MF-830 microforge (Narishige). The pipette had a resistance of 2 to 5 MΩ, measured in the extracellular solution. The reference electrode was placed in a 2% agar bridge with the same composition as the extracellular solution, but without added glucose. Experiments were performed at 23 ± 1 °C. Menthol and compound 14 stock solutions were prepared at 1 M and 3.6 mM, respectively, in DMSO. A series of perfusion solutions was prepared by diluting menthol to 500 μM menthol and compound 14 to various concentrations (from 1 to 1000 nM) in the extracellular solution. A perfusion capillary was placed near the cell, and the solution was perfused during recording. Current responses from each cell were measured under various concentrations of compound 14.Only one cell per coverslip was measured to prevent confounding effects of previous exposure to menthol and compound 14.

[0125]

[0152] Data Analysis. For each cell, the current magnitude at each concentration of Compound 14 was normalized by dividing by the maximum current measured with 500 μM menthol and no antagonist. Normalized currents from six cells were averaged at each antagonist concentration, and the standard error of the mean was calculated for each point. Data were plotted in SigmaPlot and calculated using the following equation:

number

[0126]

[0153] Liver metabolic stability

[0154] Stability in Liver Microsomes. Male CD-1 mouse liver microsomes (Lot #1710069) were purchased from XenoTech. The reaction mixture minus NADPH was prepared as described below. Compound 14 was added to the reaction mixture at a final concentration of 1 μM. The control compound, testosterone, was run simultaneously with Compound 14 in a separate reaction. Aliquots of the reaction mixture (without cofactor) were equilibrated in a shaking water bath at 37°C for 3 minutes. The reaction was initiated by the addition of cofactor, and the mixture was incubated in a shaking water bath at 37°C. Aliquots (100 μL) were removed at 0, 10, 20, 30, and 60 minutes. Compound 14 and testosterone samples were immediately combined with 400 μL of ice-cold 50 / 50 acetonitrile (ACN) / H2O containing 0.1% formic acid and internal standard to terminate the reaction. The samples were then mixed and centrifuged to precipitate proteins. All samples were assayed by LC-MS / MS using electrospray ionization. Analytical conditions were compared to PARR at time 0 to determine the percentage remaining at each time point. Half-lives and intrinsic clearances were calculated using GraphPad software, fitting to a single-phase exponential decay equation.

[0127] Reaction composition. Liver microsomes 0.5mg / mL NADPH (cofactor) 1mM Potassium phosphate, pH 7.4 100mM Magnesium chloride 5mM Analog 14 1 μM

[0128] [Table 1]

[0129] [Table 2]

[0130]

[0155] In vitro assay. C57 mice (approximately 30 g) (Harlam, Holland) were used for the study. All experiments were approved by the Institutional Animal Ethics Committee of the Universidad Miguel Hernandez where the experiments were performed and followed the guidelines of the European Economic Community and the International Association for the Study of Pain's Committee on Research and Ethical Affairs. All parts of the study regarding animal welfare were performed under veterinary supervision.

[0131]

[0156] Tremor behavior assay. The TRPM8 agonist icilin was dissolved in 20% DMSO and 1% Tween 80 in distilled water and injected intraperitoneally (ip) at a dose of 10 mg / kg. Each animal was allowed to acclimate for 30 minutes on two consecutive days before receiving icilin. Compound 14 stock was prepared in DMSO and diluted with saline for injection. Gabapentin was dissolved in saline and administered sc at a dose of 25 mg / kg, followed by an icilin injection 60 minutes later. Control animals received vehicle injections.

[0132]

[0157] Cold allodynia. Oxaliplatin (Tocris) was dissolved in water with gentle warming and injected subcutaneously (sc) at a dose of 6 mg / kg on days 1, 3, and 5. Experiments were performed on day 7 after administration. Along with the oxaliplatin injection, saline and 5% mannitol solution were injected intraperitoneally to prevent kidney damage and dehydration. Compound 14 stock was prepared in DMSO (Sigma-Aldrich) and diluted with saline for injection. Different doses (0.1 to 1 μg) of the compound were injected into the plantar surface (25 μL) of the right hind paw of mice. Cold chemical thermal sensitivity was assessed using the acetone drop method. Mice were placed in metal mesh cages and allowed to acclimate for approximately 30 minutes. Freshly prepared acetone drops (10 μL) were gently applied to the mid-plantar surface of the hind paw. A cold chemosensitive response to paw licking was recorded as a positive response (nociceptive response). Responses were measured for 20 seconds using a digital stopwatch. For each measurement, the paw was sampled twice and the average was calculated. The interval between acetone applications was approximately 5 minutes.

[0133]

[0158] Pharmacological evaluation

[0159] Ca 2+ Evaluation of TRPM8 agonist and antagonist activity using imaging. Compounds 2–15 were tested using Fura-2-based Ca imaging in HEK-293 cells stably expressing hTRPM8. 2+ Its ability to alter TRPM8 function was assessed using imaging. The latter was a gift from Thomas Voets (Laboratory of Ion Channels Research, KU Leuven, Belgium). Intracellular free Ca 2+ ([Ca 2+ ] i ) concentration was calculated as the Fura-2 fluorescence ratio (F 355 / F 380 ) was measured.

[0134]

[0160] The compounds were tested to measure the Ca2+ induced by icilin (AG-3-5). 2+ Influx ([Ca 2+ ] i Icilin was used at 500 nM and showed a maximum Ca 2+ Entry was found to occur at this concentration in our dose-response studies. Icilin was chosen to stimulate TRPM8 in this assay because it was significantly more potent (EC ) than (-)-menthol in initial concentration-response studies (Figures 13-14). 50 : approximately 70 nM vs. 6 μM), which was in agreement with previous reports.

[0135]

[0161] TRPV1 and TRPA1 agonists and antagonists Ca 2+ Flux assay (selectivity profiling). Compounds with hTRPM8 IC5 values ​​≤ 100 nM were selected for selection using a high-throughput FLIPR-based Ca2+ flux assay at Eurofins Pharma Discovery Services (St. Charles, MO). 2+Flux assays were used to assess off-target effects at two related temperature-sensitive subtypes, hTRPA1 and hTRPV1. Compounds were evaluated at a single concentration corresponding to approximately 90% target coverage at TRPM8, followed by single-point assays at 10-fold higher concentrations to demonstrate >10-fold selectivity. Agonist (intrinsic) activity was assessed in recombinant HEK293 cell lines stably expressing either human TRPA1 or TRPV1, and the maximal effect (E) of the agonists allyl isothiocyanate or capsaicin, respectively, was assessed. max Antagonist activity was normalized to Ca in these cell lines. 2+ By inhibiting AITC- or capsaicin-induced cytosolic [Ca] influx, 2+ The effects of these analogs were assessed by measuring the ability of the analogs to inhibit the increase in β-glucan-1 (TRPA1) and compared to the effects of ruthenium red (TRPA1) and capsazepine (TRPV1), which were used as reference antagonists.

[0136]

[0162] Whole-cell patch clamp electrophysiology of compound 14. The functional activity of compound 14 in calcium flux assays was confirmed using whole-cell patch clamp electrophysiology. Human TRPM8 whole-cell patch clamp electrophysiology was performed at 23±1°C on human embryonic kidney (HEK) 293 cells (ATCC CRL-1573) validated by polymorphic genetic marker testing (DNA Diagnostics Center Medical) as previously described. A series of solutions containing 500 μM menthol and various concentrations (0 to 1 μM) of compound 14 were used. Cell current responses were measured at each concentration of compound 14. IC 50 To determine the IC, normalized currents from six cells were averaged at each concentration of antagonist and the standard error of the mean was calculated for each point. Data were fit to a single-site competition model to determine the IC. 50 I got it. 50 Whole-cell patch clamp experiments were performed deliberately for saturating (500 μM) menthol concentrations because menthol currents are induced by Ca 2+Similarly, studying the inhibitory effect of compound 14 on saturating menthol allows direct comparison with other published TRPM8 antagonism studies using these conditions in whole-cell patch clamp measurements.

[0137]

[0163] In vitro metabolic stability. Compound 14 was assessed for metabolic stability in mouse liver microsomes by Absorption Systems (Exton, PA) by determining the percent remaining at 0, 10, 20, 30, and 60 minutes when incubated with mouse liver microsomes in the presence of NADPH. The half-life (t 1 / 2 ) and in vitro intrinsic clearance (CL int ) was added to the control (testosterone) and calculated.

[0138]

[0164] Results and Discussion

[0165] The available functional data for known TRPM8 antagonists, including (-)-menthyl compound 1 and AMG2850, are from rat and human TRPM8, which have unresolved structural issues. However, the structure of the avian ortholog was recently elucidated using cryo-EM. To assess the degree of sequence conservation across these species, we first performed sequence alignments of the transmembrane S1-S4 helices (VSLDs), S5-S6 helices (pore domains), pore helices (PHs), and TRP helices of avian, human, and rat TRPM8 (Figure 12). As detailed above, residues within the VSLDs and TRP helices have been reported to be important for agonist (menthol) binding, agonist (menthol, icilin) ​​response or efficacy, and voltage sensitivity. Interestingly, the high homology (83%) between full-length avian and human TRPM8 is maintained within this transmembrane region, including the ligand-binding site (86%). Furthermore, there is relatively high sequence identity (87%) between the avian and rat orthologs in this same region (Figure 12). The avian TRPM8 structure was therefore considered a reliable template for constructing a homology model of hTRPM8, with a view to first predicting plausible binding modes for the known TRPM8 antagonists (-)-menthyl compound 1 and AMG2850 and establishing appropriate structure-function relationships. The latter can then provide a structure-based approach for designing novel TRPM8 antagonist probes.

[0139]

[0166] Example 1 - MD simulation.

[0167] The structure of hTRPM8 was not available. Therefore, a homology model of hTRPM8 was first developed based on the cryo-EM structure of the white-collared flycatcher (Ficedula albicollis) (TRPM8 FA , PDB:6BPQ), which is a hybrid of hTRPM8 and full-length TRPM8. FAhTRPM8 shares 83% sequence identity with TRPM8 in the basal region and 86% in the region containing the ligand-binding site. Focusing primarily on the transmembrane region of TRPM8, consisting of the VSLD (S1-S4 helices, also known as the sensing domain or SD) and pore domain, as well as the TRP helix, a homology model of hTRPM8 was constructed using the sequence from Gln671 to Asn1010 (340 residues). While the VSLD and TRP helices bind small molecule agonists, as discussed above, isolated VSLD (including the pre-S1 domain) has been reported to recapitulate a binding phenotype consistent with functional activation of full-length hTRPM8 (1104 residues).

[0140]

[0168] Ca 2+ The ion was placed in a VLSD coordinated to Glu782, Gln785, Asn799, and Asp802 to demonstrate that the human model more closely resembles the cryo-EM structures of related human melastatin subtypes M2 (PDB 6MJ2) and M4 (PDB 6BQV), and our Ca(II) complex employs the TRPM8 agonist icilin as an activator. 2+ The structural context of the flux studies was provided (Table 1). These structures show Ca coordinated to four side chains (three of which are conserved between TRPM8, TRPM2, and TRPM4) that are similarly oriented in the VLSD. 2+ Grabs ions: Glu782 (TRPM8, S2 helix) / Glu843 (TRPM2, S2) / Glu828 (TRPM4, S2); Gln785 (TRPM8, S2) / Gln846 (TRPM2, S2) / Gln831 (TRPM4, S2); and Asn799 (TRPM8, S3) / Asn869 (TRPM2, S3) / Asn865 (TRPM4, S3). The remaining non-conserved Ca 2+Considering the binding residues, Asp802 (S3) was selected as the final chelating amino acid to complete the tetrahedral complex, corresponding to Asp868 (S3 helix) in the M4 subtype. Notably, both Asn799 and Asp802 are known icilin-sensitive residues. The recently reported icilin-bound structure of TRPM8 (PDB 6NR3, 3.4 Å) provides a now well-defined Ca2+ complex, consistent with the homology model. 2+ Ca binds to these four residues within the binding site. 2+ ions are revealed.

[0141]

[0169] Subsequently, (-)-menthyl compound 1, AMG2850, and compound 14 were docked into the ligand-binding site of hTRPM8, and 100 ns molecular dynamics (MD) simulations were performed for each compound within hTRPM8, and the results were analyzed as detailed below. 2+ (-)-Menthyl 1 (IC) was described as a highly potent and selective TRPM8 antagonist in rat TRPM8 flux assays. 50 vs. 20 μM menthol, 20 ± 2 nM; IC 50 vs. 0.25 μM icilin, 50±10 nM) is currently used in the literature as a TRPM8 tool molecule (also referred to as OMDM233), along with AMG2850.

[0142]

[0170] Example 2 - (-)-Menthyl Compound 1 and hTRPM8.

[0171] As shown in Figure 2C, the results showed that the root mean square deviations (RMSDs) of hTRPM8 (approximately 3.9 Å) and (-)-menthyl compound 1 (1.8 Å) both remained stable after 50 ns during the simulation, indicating that a time scale of 100 ns was appropriate.

[0143]

[0172] The biphenyl of compound 1, which protrudes toward the TRP helix at the bottom of the binding cavity in an extended conformation, remained stable during MD simulations; it forms strong hydrophobic interactions with Asn741 (S1, approximately 4.0 Å, not shown) and Val849 (S4, 4.4 Å), occupying a similar space as the corresponding methoxyphenyl of WS-12, as shown in Figure 2B. This pose is consistent with SAR studies on this scaffold, where the biphenyl substitution results in the highest TRPM8 potency of all analogs studied.

[0144]

[0173] In contrast to the biphenyl moiety, the flexible (-)-menthyl moiety of compound 1 was found to tolerate conformational changes during MD simulations when its binding mode was compared between pre-MD (Figure 2A) and post-MD (Figure 2B). However, interactions between compound 1 and some residues could be observed during MD. For example, the (-)-menthyl moiety of compound 1 interacts with the conserved Arg1008 (TRP helix, 3.5 Å, not shown) (Figure 2B), which assumes a folded conformation similar to that seen in the WS-12-bound structure and may represent a common TRPM8-binding residue for small molecule ligands. To explore the contribution of these residues to the binding of compound 1, we decomposed the free energy using the MM / GBSA method, as shown in Figure 2D. The energy decomposition revealed that Arg1008 significantly contributed to the binding of compound 1. Although the distance between compound 1 and Arg842 (S4) was approximately 3.9 Å, the (-)-menthyl moiety approached the conserved Leu778 (S2, approximately 3.8 Å, not shown) during MD simulations (Figure 2B), overlapping with the (-)-menthyl and nitrophenyl binding regions of WS-12 and icilin, respectively, resulting in a smaller contribution of Arg842 to the binding free energy than Leu778. The results are consistent with those from free energy decompositions using the MM / GBSA method (Figure 2D). Interestingly, the (-)-menthyl group does not contact Tyr745 (S1), as in the WS-12-bound structure, forming extensive hydrophobic interactions with the base of the orthosteric site, likely due to the tethering properties of the biphenyl, as suggested for (-)-menthol by radioligand displacement studies. This study represents the first foray into the investigation of menthol-based antagonist-mediated molecular events using TRPM8 structural biology described to date.

[0145]

[0174] Example 3 - AMG2850 and hTRPM8.

[0175] A 100-ns MD simulation was also performed for AMG2850 and hTRPM8. As shown in Figure 3C, the RMSD of hTRPM8 was found to reach equilibrium (approximately 4.4 Å) after 60 ns. The RMSD of AMG2850 remained constant at 1.6 Å (Figure 3C). Due to the stability of AMG2850, a 100-ns time scale was reasonable to explore its possible binding mode. Comparing the binding mode of AMG2850 between pre-MD (Figure 3A) and post-MD (Figure 3B) revealed that several key interactions between AMG2850 and hTRPM8 were stably maintained. For example, the conserved Arg842 (S4) forms strong hydrogen bonds with the urea carbonyl of AMG2850 (3.1 / 3.0 Å), similar to the amide carbonyl of WS-12 and the dihydropyrimidinone carbonyl of icilin, suggesting a common H-bond acceptor characteristic for TRPM8 ligand recognition by this common residue. Consistent with this predicted interaction, SAR studies of the AMG2850 precursor series containing a tetrahydrothienopyridine core emphasize the importance of the urea moiety, and deletion of this group abolishes TRPM8 activity (derivatives 24-26 reported by Tamayo et al.). MD results also show that the conserved Trp798 (S3) forms a hydrogen bond with the trifluorophenyl CF3 group of AMG2850 at a distance of 3.2 Å, consistent with SAR studies of the tetrahydrothienopyridine precursor series, where 4-CF3 confers optimal functional and pharmacokinetic properties. Interestingly, the inactive S enantiomer of a related tetrahydroisoquinoline analog of AMG2850 positions this trifluorophenyl in the opposite direction, away from Trp798, whereas the corresponding R enantiomer does not activate the TRPM8 IC. 50It has been reported to have a β-reactivity of 56 ± 24 nM (derivatives 87-88 reported by Tamayo et al.). Furthermore, the main chains of Leu841 (S4) (distance: 4.2 Å, not shown) and Arg842 (distance: 3.3 Å, not shown) interact with the trifluorophenyl CF3 group of AMG2850 through hydrophobic interactions. Tyr1005 (a conserved residue, TRP helix) forms a strong hydrophobic interaction with 5,6,7,8-tetrahydro-1,7-naphthyridine at a distance of 4.4 Å. This residue (TRPM8) FA The cis-amino acid residue (Tyr1004 in AMG2850) hydrogen bonds with the icilin nitro group and the WS-12 amide nitrogen, suggesting another common TRPM8-binding residue, consistent with functional studies of menthol. Again, this interaction is consistent with the SAR data of this series, suggesting the importance of hydrophobic interactions between ion channels and azatetrahydroquinolines. Modifications including removal of the aromatic ring, one-carbon extension of the piperidine (to an azepine), and conformational constraints by methyl substitution at position 8 result in significant loss or negation of TRPM8 activity (derivatives 32, 72, and 86 reported by Horne et al. and Tamayo et al.), which may disrupt this hydrophobic interaction. Alternatively, these analogs may disrupt the hydrogen bond between Arg842 and the urea carbonyl of AMG2850, resulting in a dramatic loss of TRPM8 activity.

[0146]

[0176] On the opposite side of the molecule, Asp781 (S2) was observed to interact with the trifluoropropanyl CF3 via a hydrogen bond at a distance of 3.4 Å. Similar to the previously discussed interactions, this interaction is consistent with SAR studies of this region on azatetrahydroquinolinone and tetrahydroisoquinoline scaffolds, where the trifluoropropanyl group confers high TRPM8 potency. Together with hydrogen-bonding interactions with Arg842 and Trp798, these orient AMG2850 in a T-shaped conformation, with both ends of the molecule spanning the top of the VSLD pocket, in contrast to the extended conformation seen in the (-)-menthyl compound 1. On the other hand, the azatetrahydroquinoline ring of AMG2850, like the biphenyl in compound 1, penetrates deep into the cavity toward the TRP helix. Furthermore, Leu778 was observed to form strong hydrophobic interactions with trifluoropropanyl CF3 at a distance of 3.6 Å (not shown), similar to the (-)-menthyl of compound 1. These results were consistent with those of the free energy decomposition using the MM / GBSA method (Figure 3D).

[0147]

[0177] In particular, from the MD study, the two antagonists studied and Ca 2+ No direct interactions between binding residues were found, which may point to a possible structure-based explanation for their ability to function as antagonists. An interaction was observed between AMG2850 and Arg842, which is similar to what was observed in the human TRPM4 structure (the corresponding TRPM4 residues are Arg905 and Asp868), and is related to the tetrahedral Ca2+ binding by Asp802 in human TRPM8. 2+ Such an interaction with Arg842 could theoretically reinforce the complex. 2+ On the other hand, TRPM8 may act to destabilize the channel, resulting in channel inhibition. FA (avian) structure, the corresponding residue Arg841 is Ca 2+ It is not shown to interact with binding residues, but instead forms direct interactions with the icilin carbonyl.

[0148]

[0178] Example 4 - Structure-based design.

[0179] By overlaying the predicted binding modes of AMG2850 and (-)-menthyl compound 1 from MD simulations, we observed several key residues that form hydrophobic pockets within the VSLD in S2 and the TRP helix (Figure 4). Leu778 (S2) interacts with both the (-)-menthyl and trifluoropropanyl groups of compound 1 and AMG2850. In the same vicinity, Arg1008 (TRP helix) forms key hydrophobic interactions with the (-)-menthyl group. These interactions allow the above groups to overlap in the VSLD, suggesting that the compound 1 scaffold can be substituted with other lipophilic groups, such as ring-expanded analogs of the core cyclohexyl ring, bi- and tricyclic rings, aromatic-containing groups, and spiro-substituted bicyclic rings.

[0149]

[0180] These substitutions result in ratiometric Ca 2+ By imaging (a representative experiment is shown in Figure 5, and the corresponding histogram is shown in Figure 15) human TRPM8, we explored the compound 1 scaffold while maintaining the biphenyl (because this was the optimal substitution for potent TRPM8 antagonist activity from previous SAR studies). To this end, various lipophilic substitutions of the (-)-menthyl moiety of compound 1 were prepared by standard EDCI / HOBt-mediated amidation of commercially available substituted amines and [1,1'-biphenyl]-4-carboxylic acid I-1, as shown in Scheme 1 below.

[0150] [ka] Scheme 1. Synthesis of compounds 2-15. Reagents and conditions: (a) R1-NH2, EDCI, HOBt, Et3N.

[0151]

[0181] Example 5 - Structure-activity relationship (SAR) analysis of (-)-menthyl compound 1.

[0182] Dose-response studies of the prototype icilin in this assay demonstrated that Ca 2+ Influx EC of 74 ± 3 nM 50 icilin-induced Ca2+ at 120–200 nM (Figure 13), which appears to be more potent than previously reported values, which are in the range of 120–200 nM, but this is likely due to differences in cell type (CHO vs. HEK cells) or species-dependent variations in icilin sensitivity (human vs. mouse). 2+ The signal began to plateau at 500 nM. RQ-00203078 was used as a positive control and reference standard for SAR studies due to its potent TRPM8 antagonist activity. In the assay, RQ-00203078 inhibited icilin-induced Ca 2+ The signal was measured at an IC of 2.96 ± 0.99 nM. 50 (Figure 16), which is consistent with the 30 μM menthol-induced Ca2+ increase in HEK cells expressing hTRPM8. 2+ This is lower than previously reported values ​​for influx (approximately 8 nM).

[0152]

[0183] For the compounds synthesized here, IC 50 The values ​​are shown in Table 1 and indicate the icilin-stimulated Ca 2+ The concentration was expressed as the concentration required to produce half-maximal inhibition of influx. (-)-Menthyl compound 1 was also resynthesized using a previously reported method and demonstrated potent antagonist activity at rTRPM8 in the calcium flux assay (IC3 for 20 μM menthol). 50 , 20 ± 2 nM; IC for 0.25 μM menthol 50 Due to its weak intrinsic (agonist) activity at hTRPV1 and rTRPA1, compound 1 was used as an additional standard for biochemical assays at hTRPM8. Interestingly, compound 1 showed dramatically reduced potency (IC of 16 ± 1 μM) in assays in HEK-293 cells transfected with human TRPM8. 50 ) (Table 1). IC observed in calcium flux assays with human versus rat TRPM8 50The difference in values ​​suggests species differences among TRPM8 orthologs for this compound. Despite high sequence conservation, species differences are known to exist between different TRPM8 orthologs. Additional studies with rTRPM8 will be performed on all analogs in this series to determine whether similar potency shifts are observed. Human TRPM8 is highly homologous to its rat ortholog, with 96% sequence identity in the VSLD domain, pore domain, and TRP helix (residues 734–1009, calculated by Clustal Omega; data not shown). However, there are a few different amino acid residues, which may account for the discrepancies observed between these orthologs in calcium flux assays. One such residue, at position 1007 in the TRP helix, is located in the binding pocket (serine in hTRPM8, asparagine in rTRPM8). Studies to further characterize 1 are ongoing and will be reported in due course.

[0153]

[0184] By removing the chirality of compound 1 to obtain the isomer mixture compound 2, the assay described herein (hTRPM8 IC 50 The hTRPM8 activity at 468 ± 1 nM (Table 1) was increased 30-fold, indicating that the mixture contains isomers with more optimal stereochemical configurations at the C1, C2, and C5 positions than compound 1. Compared to the menthol isomer mixture compound 2, removal of the C5 methyl and C2 isopropyl groups (as in compound 3) and conformational constraint of the core cyclohexyl ring (as in compound 4) resulted in a reduction in TRPM8 potency in the μM range, highlighting the conformational flexibility of the entire (−)-menthyl scaffold and between the cyclohexyls, which may displace hydrophobic interactions with Leu778 and Arg1008, as suggested by our molecular dynamics studies.

[0154] Table 1. Cellular Ca in HEK-293 cells stably expressing hTRPM8 2+ IC of compounds in nM determined by flux assay and expressed as mean ± SEM from three independent experiments 50Value.IC 50 Icilin-induced Ca 2+ It is defined as the concentration of compound that inhibits 50% of the invasion. [Table 3-1]

[0155] [Table 3-2]

[0156]

[0185] On the other hand, the ring-expanded analogs (cycloheptyl compound 5 and cyclooctyl compound 7) improved hTRPM8 potency 8-9-fold over compound 2, with IC 50 The values ​​were 52 ± 1 nM and 62 ± 1 nM, respectively, suggesting the ability to capture additional interactions in the pocket. To rationalize these results, compounds 5 and 7 were docked into the hTRPM8 homology model (Figure 6). For both compounds, the biphenyl ring was located between the S1 and S4 helices and the TRP helix, similar to compound 1. The biphenyl ring of both analogs formed strong hydrophobic interactions with Val849 (conserved, S4, 3.8 / 3.8 Å), in addition to Phe738 (conserved, S1, 3.5 / 3.7 Å), Leu1001 (conserved, TRP helix, 3.7 / 3.7 Å), and the menthol- and icilin-sensitive Tyr1005 (conserved, TRP helix, 4.0 / 4.0 Å), the same interactions seen for the compound 1 biphenyl. The 1-phenyl group forms edge-to-face π-π stacking with both Phe738 and Tyr1005. These additional interactions provide a Ca 2+This may contribute to the enhanced potency of these analogs in flux assays. Interestingly, the 5,6,7,8-tetrahydro-1,7-naphthyridine of AMG2850 forms hydrophobic contacts with Tyr1005 (Figure 3) in the same vicinity as the 1-phenyl of compound 1 (Figure 4). This reinforces the concept of Tyr1005 as a common small molecule binding residue. The amide NH and carbonyl O of compounds 5 and 7 both interact with Arg1008 (a conserved TRP helix) through strong hydrogen-bonding interactions, and this residue may drive their potent functional activity relative to that seen in compound 1, which only forms hydrophobic contacts with the (-)-menthyl moiety. These results suggest that Arg1008 is a key residue for the recognition of both compound 1 and its analogs. Furthermore, the cycloheptyl and cyclooctyl moieties of both ligands form similar hydrophobic interactions with three residues on the opposite side of the VSLD from Leu778 and Arg1008, including the potential and icilin-sensitive Arg842 (conserved, S4, 4.2 / 4.0 Å), icilin-sensitive His845 (conserved, S4, 3.7 / 4.0 Å), and Ile846 (conserved, S4, 3.6 / 3.5 Å). Collectively, these results suggest that the orthosteric site can accommodate larger hydrophobic substitutions than those seen in compound 1, as well as several other lipophilic residues mentioned above, but that the biphenyl provides tethering interactions toward the floor of the cavity.

[0157]

[0186] Similar to compounds 3 and 4, conformational constraint of compound 5 (to bicyclo[3.2.1]octan-3-yl, compound 6) resulted in a sharp decrease in potency, likely due to the loss of multiple H-bonding contacts to Arg1008. Exploration with bicyclic and tricyclic ring replacements was undertaken to further explore the lipophilic space around our series.

[0158]

[0187] Decahydronaphthalen-1-yl, compound 8, resulted in a significant drop in hTRPM8 potency in the μM range relative to compounds 5 and 7, indicating that the pocket is volume-discriminating. Similarly, tetrahydronaphthalen-1-yl (compound 9) suffered a three-fold loss in potency relative to compound 8, again suggesting the need for flexibility in this region of the scaffold. In sharp contrast, a mixture of the two isomers, decahydronaphthalen-2-yl (compound 10), exhibited a 3,500-fold enhancement in TRPM8 potency (IC) relative to compound 8. 50 :6±1 nM), 10-fold more potent than both the cycloheptyl (compound 5) and cyclooctyl (compound 7) analogs, suggesting that the decahydronaphthalen-2-yl ring occupies a lipophilic pocket, maximizing available hydrophobic interactions. Consistent with the trends in SAR seen with compounds 8 and 9, substitution with a tetrahydronaphthalen-2-yl group (compound 11) reduces hTRPM8 potency by 9-fold, yet the nM potency at hTRPM8 remains below IC 50 Chromatographic separation of one of the isomers of compound 10 to give compound 12 successfully yields potencies in the single-digit nM range, with an IC 50 The IC value was 1.4 ± 1.0 nM, 4-fold higher than that of the diastereomeric mixture. Compound 10, like the single isomer compound 12, may form multiple contacts with residues in the VSLD, conferring high hTRPM8 potency. LC-MS analysis of compounds 10 and 12 revealed that compound 10, a mixture of two diastereomers, consists of >85% compound 12 isomer, thus increasing its potency. 50 It has been shown to provide value.

[0159]

[0188] The relative stereochemistry of compound 12 is shown below: 1 H, 13The stereochemistry was established by C, COSY, NOESY, HSQCAD, HMBCAD, and H2BC (Table 2). Analysis of the NMR data, including comparison of the decalin ring proton and carbon chemical shifts with literature values, indicates that this compound is a cis-decalin with a biphenylamide moiety at position 2. Analysis of the NOESY data indicates that the amide group is trans to the decalin bridge proton (see structure below; absolute stereochemistry cannot be established).

[0160] Table 2. N-((2SR,9RS,10SR)-decahydronaphthalen-2-yl)-[1,1'-biphenyl]-4-carboxamide (compound 12) 1 H- and 13 C-NMR chemical shift assignments. [Table 4]

[0161]

[0189] The structure was determined to be cis-decalin because the carbon and proton chemical shifts were consistent with this structure (see Dodziuk et al.). The cis-decalin bridge carbons (C9, 10) resonate at 36.1 ppm, while those in trans-decalin resonate at 42.5 ppm. Furthermore, the bridgehead protons resonate at lower ppm in trans-decalin than observed in this structure (1.91, 1.68 ppm compared to 0.87 ppm for trans-decalin). See also Browne et al.

[0162]

[0190] The relative stereochemistry of the amide moieties was more difficult to ascertain. NOESY data was consistent with the proposed structure. However, there was significant chemical shift overlap, particularly with H10 and H1, making unambiguous assignment impossible. NOESY data established that H9 (1.91 ppm) and H2 (4.01 ppm) were on the same plane. This result, combined with the chemical shift data, was consistent with cis-decalin substituted at the trans-2 position with a biphenylcarboxamide.

[0163]

[0191] Replacement of the (-)-menthyl group in compound 1 with a spiro-substituted bicycle was then explored. Spiro[5.5]-undecan-3-yl (compound 13) retained potency similar to compounds 5 and 7, with an IC 50 was 40±1 nM, which is not in the high nM range as decahydronaphthalen-1-yl (compounds 10 and 12), suggesting that the capacity of the complementary region of the receptor cavity is fixed and cannot tolerate the spiro configuration of the two cyclohexyl rings.

[0164]

[0192] The one-carbon ring contraction of compound 13 (to spiro[4.5]decan-8-yl, compound 14) recapitulated the potent activity of the decahydronaphthalen-1-yl isomer (compound 12) (IC 50 : 2.4 ± 1.0 nM), an activity comparable to that of the highly potent TRPM8 antagonist RQ-00203078 in the assay. Spiro[4.5]decan-8-yl (compound 14) was similar in potency to compound 12, further suggesting that the nature of the pocket is constrained or distinct. The binding site for this series was unambiguously determined using structural biology techniques, such as cryo-EM or X-ray crystallography, to obtain the ligand-bound structure of human TRPM8 coupled with mutagenesis studies. Currently, the structure of human TRPM8 is unknown. Notably, compound 14 shares several structural features in common with other potent TRPM8 antagonists reported in the scientific and patent literature. Both spiro-isoxazoline and biphenyl aromatic configurations have been shown to be effective against highly potent benzimidazole-based TRPM8 antagonists, such as JNJ41876666 / TC-I2014 (cTRPM8 IC 50 (icilin: 0.8 nM). Another TRPM8 antagonist reported by Glenmark Pharmaceuticals, (R)-(-)-10e (hTRPM8 IC 50 ( 45 Ca 2+Uptake): 8.9 nM) includes 3,4-dihydrospiro[chromene-2,4'-piperidine. Similarly, Raqualia Pharma has reported a series of azaspiro TRPM8 antagonists containing ring systems in which a ketone is linked to a phenyl ring para-substituted with an aromatic ring and a heterocycle, such as 1-oxa-3-azaspiro[4.5]decan-2-one, 1,3-diazaspiro[4.5]decane-2,4-dione, and 1-oxa-3-azaspiro[4.5]decane-2,4-dione.

[0165]

[0193] A dose-response curve for compound 14 was then constructed from the data shown in Figure 15. Compound 14 was selected for further characterization given that, unlike compound 12, it does not have a chiral center. As shown in Figure 17, compound 14 inhibited the icilin-induced Ca 2+ Inflow IC 50 = 2.4 ± 1.0 nM, and at higher concentrations, 2+ Inflows will be almost eliminated (Figures 15 and 17).

[0166]

[0194] Ca 2+ To determine the ability of compound 14 to inhibit menthol in the flux assay, the menthol response was first assessed in HEK-293 cells stably expressing hTRPM8, with an EC of approximately 6 μM. 50 We found that menthol potency was comparable to that previously reported for hTRPM8 in similar calcium imaging of HEK293 cells (Figure 14). Compound 14 still inhibited icilin-induced TRPM8-mediated Ca 2+ The lowest concentration capable of causing a significant reduction in menthol-induced TRPM8-mediated Ca entry was 3 nM (Figure 17). Compound 14, at the same lowest (i.e., 3 nM) concentration, suppressed the maximal (100 μM) menthol-induced TRPM8-mediated Ca entry. 2+ As can be seen in Figure 18B, 3 nM of compound 14 also inhibited the TRPM8-mediated Ca(2+) entry evoked by menthol. 2+Invasion was significantly (P<0.01) reduced. These studies, in addition to our SAR studies performed with icilin, provide additional support for exploring the effects of compound 14 in this assay using menthol as the agonist.

[0167]

[0195] Adamantyl (compound 15) is an IC 50 16±1 nM, yielding slightly lower potency than compound 14, indicating that the tricyclic ring was well tolerated as well as the bicyclic rings (compounds 10-14). 2+ Antagonist activity of compounds 10, 12, 14, and 15 in the flux assay showed IC values ​​in the ≤10 nM range in cells transfected with human TRPM8. 50 PF-05105679 (Pfizer, Phase 1, hTRPM8 IC 50 =181nM), AMG333 (Amgen, Phase 1, hTRPM8 IC 50 = 13 ± 4 nM), AMG2850 (Amgen), RQ-00203078 (RaQualia Pharma), AMTB (Bayer), arylglycine derivative 12 and vinylcycloalkyl-substituted benzimidazole 25 (Janssen), DFL23448 and DFL23693, M8-B, M8-An, tryptophan derivative 14, etc. 2+ Flux activity exceeds or is comparable to Ca 2+ hTRPM8 IC in flux assays 50 None of the compounds with values ​​≦100 nM (compounds 5, 7, 10-15) were able to stimulate the channel alone at a single high concentration of 10 μM (FIG. 19), which is consistent with the results obtained in our antagonist assays.

[0168]

[0196] Example 6 - In vitro selectivity profiling with TRPA1 and TRPV1.

[0197] The selectivity profiles of novel compounds 5, 7, and 10-15 were then determined for two temperature-related TRP subtypes, hTRPA1 and hTRPV1. Many TRP ligands have opposite behaviors; for example, the TRPM8 agonist menthol blocks both TRPV1 and TRPA1 but activates TRPA1 at low concentrations. Similarly, the TRPV1 agonist capsaicin can inhibit TRPM8-mediated responses. On the other hand, TRPV1 antagonists such as capsazepine, BCTC, and SB-452533 block TRPM8 in a dose-dependent manner. These studies suggest overlapping ligand recognition between TRPM8, TRPA1, and TRPV1. Like TRPM8, TRPA1 is activated by low temperatures in vitro and in vivo, albeit at slightly lower temperatures. Icilin also activates TRPA1 at μM concentrations of Ca. 2+ Active in flux assays.

[0169]

[0198] This TRPA1 Ca 2+ In the flux assay, dose-response studies of the TRPA1 agonist AITC revealed an EC of 7.62 ± 0.89 μM. 50 The TRPA1 antagonist ruthenium red, used as a standard and positive control in the assay, significantly inhibited AITC (10 μM)-activated [Ca 2+ ] i Release was measured with an IC of 29 ± 6 nM in response to the effect of 80 μM AITC. 50 reported an IC of 162 ± 33 nM in the same range as Klionsky et al. 50 The TRPV1 agonist capsaicin (EC 50 19±2.5 nM, Figure 22) and the antagonist capsazepine (IC 50 EC4 for 451 ± 48 nM, Figure 23) 50 and IC 50 is similar to the value reported by El Kouhen et al. The curves included in Figures 20-23 are listed with ±95% confidence intervals.

[0170] Table S1. TRPA1 agonist data (E max (Percentage activation normalized to control). All data are E for the reference agonist AITC. max It is standardized against [Table 5]

[0171] Table S2. TRPA1 antagonist data (EC 80 (Percentage inhibition normalized to control). All data are EC50 values ​​for the reference agonist AITC. 80 It is standardized against [Table 6]

[0172] Table S3. TRPV1 agonist data (E max (Percentage activation normalized to control). All data are E for the reference agonist capsaicin. max It is standardized against [Table 7]

[0173] Table S4. TRPV1 antagonist data (EC 80 (Percentage inhibition normalized to control). All data are EC50 values ​​for the reference agonist capsaicin. 80 It is standardized against [Table 8]

[0174]

[0199] Among the compounds with significant TRPM8 antagonist activity, all analogs except compounds 5, 7, and 11 had significantly higher hTRPM8 IC values ​​than their hTRPM8 IC values. 50 At a concentration roughly equivalent to twice the previous value and more than 10 times the previous value, both hTRPV1 and hTRPA1 showed Ca 2+The compounds had negligible intrinsic (agonist) and antagonist activity in the flux assay. In particular, none of the compounds exhibited the E max When normalized for concentration, neither of these analogs showed more than 25% activation of hTRPA1 or hTRPV1 at either concentration tested. Similarly, none of these analogs showed an EC 80 Concentrations of AITC and capsaicin (10 μM and 0.1 μM, respectively) failed to inhibit either subtype by more than 25%. For example, the hTRPM8 IC 50 Compound 10 did not activate or inhibit hTRPA1 or hTRPV1, even at a 17-fold higher concentration of 6±1 nM. Similarly, compounds 12, 13, 14, and 15, respectively, were found to be significantly lower than their hTRPM8 IC 50 The compounds in this series have no effect on hTRPA1- and hTRPV1-mediated responses at concentrations 21-, 25-, 13-, and 19-fold higher than the values ​​of 1.4±1 nM, 40±1 nM, 2.4±1.0 nM, and 16±1 nM, respectively. Thus, many compounds in this series are at least 10-fold selective for TRPM8 over the related thermal TRPs, TRPA1 and TRPV1.

[0175] Table 3.Ca 2+ Intrinsic and antagonist functional activities of selected biphenylamides at TRPA1 and TRPV1 receptors as determined in flux assays. [Table 9]

[0176]

[0200] Example 7 - Whole-cell patch clamp electrophysiology of compound 14.

[0201] Whole-cell patch clamp electrophysiology was used to further explore and confirm the antagonist activity of compound 14 at hTRPM8, using the cognate ligand menthol to stimulate the channel (Figure 7). In patch clamp experiments, activation of TRPM8 by icilin in transfected HEK-293 cells or TRPM8-expressing Xenopus oocytes was observed in response to extracellular Ca. 2+ Furthermore, icilin activates the channel with highly variable latencies and significant desensitization, an effect not seen with menthol. Taking these into consideration, we further explored the ability of compound 14 to inhibit menthol-mediated responses in hTRPM8, as described in detail in a previous publication. 2+ In contrast to the pH-dependent icilin-induced response, menthol induces robust TRPM8 activation in voltage-clamp assays, allowing for better comparative studies. With these considerations in mind, we evaluated the ability of compound 14 to affect currents induced by the agonist menthol.

[0177]

[0202] Ca using icilin 2+ Consistent with the flux studies, this compound inhibited menthol-induced TRPM8 responses with an IC of 64 ± 4 nM. 50 in a concentration-dependent manner, demonstrating that compound 14 is a true, functionally robust TRPM8 antagonist capable of inhibiting TRPM8 responses induced by different chemical stimuli at nM concentrations. The antagonist activity of compound 14 is six-fold greater than that of tryptamine-based antagonists in the same assay, and has similar potency to β-lactam antagonists containing three labile ester groups. The IC of compound 14 50 Although the IC values ​​do not approach those of known TRPM8 antagonists in PBMC in this assay, 50This benzyloxy-phenylmethylcarbamate analog of AMTB, with its labile ester and carbamate groups, appears to have limited utility as a chemical probe. PBMCs give variable responses in different behavioral models of neuropathic pain and fail to block cold sensitization in the CIPN model. Collectively, compound 14 overcomes assay-specific nuances associated with different chemical activators, as evidenced by the Ca sensitization observed when both icilin and menthol were loaded. 2+ Compound 14 demonstrates robust and highly potent antagonist activity in both flux and whole-cell patch clamp assays. Compound 14 has been well characterized pharmacologically and possesses TRPM8 activity in several assays relative to other small molecule TRPM8 ligands, demonstrating its potential as a chemical tool for exploring TRPM8-mediated pharmacology. As discussed below, compound 14 interacts with Arg842 and Tyr1005, which have also been shown to bind icilin and the menthol analog WS-12. Binding to these residues enhances Ca2+ binding, respectively. 2+ This may suggest why compound 14 is able to inhibit both icilin- and menthol-mediated responses in flux and electrophysiological assays, but site-directed mutagenesis studies may provide further insight.

[0178]

[0203] Example 8 - Compound 14 and hTRPM8.

[0204] To rationalize the potent antagonist activity of compound 14 in the context of the human TRPM8 homology model, experiments were then performed by conducting 100 ns MD simulations. Briefly, 100 ns MD simulations were performed on the highly potent antagonist spiro[4.5]decan-8-yl compound 14 at hTRPM8. The RMSD (1.9 Å) of hTRPM8 (approximately 3.9 Å) and compound 14 remained stable after 30 ns, as shown in Figure 8C, indicating that a 100 ns time scale is appropriate.

[0179]

[0205] As shown in Figure 8A, the cyclopentyl group of compound 14, like the cycloheptyl and cyclooctyl groups of compounds 5 and 7, forms strong hydrophobic interactions with the conserved Arg842 (S4, side chain, 3.4 Å) and Ile846 (S4, 4.0 Å) residues in the lower S4 helix (Figure 6). The biphenyl contacts the conserved Leu1001 (approximately 3.1 Å, not shown) and Tyr1005 (menthol-sensitive, 3.8 Å) residues in the TRP helix before MD simulation. Figure 8B shows the binding pose of compound 14 in TRPM8 after MD simulation. It was observed that the interaction between the biphenyl group of compound 14 and Ile846 (3.6 Å), Leu1001 (3.3 Å, not shown), and Tyr1005 (3.4 Å) remained stable during MD, as shown in Figure 8B. Rather, Ile846 shifts to make hydrophobic contact with the biphenyl group, as do Leu1001 and Tyr1005, whose interactions with Leu1001 and Tyr1005 are again consistent with the docking poses of compounds 5 and 7, as previously discussed.

[0180]

[0206] Ile846, Leu1001, and Tyr1005 anchor the biphenyl to the bottom of the VSLD, where it is more deeply buried than the biphenyl in compound 1, again suggesting a plausible rationale for the agonist-versus-antagonist-mediated behavior of these species. Importantly, the hydrophobic interactions observed between Tyr1005 and the biphenyl are also seen in the post-MD pose of AMG2850. This residue contacts WS-12 and icilin through polar interactions, as previously discussed, reinforcing the notion of Tyr1005 as a common TRPM8 residue for ligand recognition. Unlike compounds 1 and WS-12, the aromatic-containing groups do not overlap in the VSLD.

[0181]

[0207] Surprisingly, the spiro[4.5]decan-8-yl group was found to maintain hydrophobic contact with Arg842 via the cyclohexyl ring. Energy decomposition of key residues, together with Ile846, Leu1001, and Tyr1005, further supports the notion that these four residues may contribute to a greater extent than other residues to the recognition of compound 14 in TRPM8, as shown in Figure 8D. Arg842 is located on the opposite side of the VSLD to the menthol-binding site and is involved in the binding of bound Ca. 2+ The ion and coordination-binding residues in the S2-S3 helix are close to each other, another consensus residue for small molecule binding suggested by previous cryo-EM and MD studies on AMG2850. This forces the molecule into a broad conformation. This region of the VSLD orthosteric site (the lower S2 helix and the S3-S4 helix) contains several hydrophobic and polar residues and can preferentially accommodate larger hydrophobic substitutions for our biphenylamide series, such as those found in our potent nanomolar antagonists / compounds 5, 7, and 10-15, relative to the menthol-binding region in the S1 and upper S2 helices, providing a structural context for our experimentally observed SAR trends. Residues in this vicinity, particularly Glu782 and Arg842 (TRPM8), are also involved. FA Arg841) and His845 (TRPM8 FA His844 in TRPM8 has been reported to adopt multiple conformations, allowing TRPM8 to bind both WS-12 and icilin.

[0182]

[0208] The presence of bulky residues, such as Trp798 (S3) and His845 (S4), 3.6 and 3.8 Å away from the spirocyclohexyl group, may act to sterically repel the decahydronaphthalen-1-yl and tetrahydronaphthalen-1-yl rings of compounds 8 and 9, effectively reducing their TRPM8 potency to the μM range relative to other analogs in our series that have a greater degree of conformational flexibility in this region (as in compounds 5 and 7) or a more optimal bicyclic configuration (compounds 10–14).

[0183]

[0209] Interestingly, compound 14 does not interact with Arg1008 (as in compounds 1, 5, and 7) or form a hydrogen bond with it, but instead makes extensive hydrophobic contacts within the binding cavity, similar to those seen in the recently reported structures of the antagonists AMTB and JNJ41876666 / TC-I2014 bound to Parus major (parrot) TRPM8 (pmTRPM8) (PDB 6O6R and 6O72, respectively). Comparison of the post-MD pose of compound 14 with the JNJ41876666 / TC-I2014 complex structure revealed that the biphenyls of both antagonists overlap within the VSLD, supporting our MD results, although the spiro-containing moieties are oriented oppositely within the pocket. The opposite orientation observed for the spiro[4.5]decan-8-yl of compound 14 relative to the spiro-isoxazoline of JNJ41876666 / TC-I2014 is due to either group projecting away from the amide (trigonal planar geometry, 120°) relative to the conformationally rigid benzimidazole.

[0184]

[0210] Example 9 - In silico selectivity profiling with TRPA1 and TRPV1

[0211] To rationalize the selectivity profile of compound 14, we docked this compound into the cryo-EM structures of rTRPV1 (PDB 3J5R) and hTRPA1 (PDB 3J9P) and compared these poses with the pre-MD (docked) poses in the hTRPM8 homology model. Interestingly, the binding pockets of TRPM8, TRPV1, and TRPA1 occupy distinct regions of the VLSD (S1–S4), the pore domain formed by S5–S6, and the pore helix (Figure 9). The vanilloid ligand, resiniferatoxin (RTX), a capsaicin-like homovanillyl ester antagonist, and the competitive antagonist capsazepine bind TRPV1 residues at 2.9 Å and 3.4 Å in the S3 and S4 helices, and in the S4–S5 linker. Together with the liganded cryo-EM structure of avian TRPM8, which defines binding pockets within the S1-S4 helices and the TRP helix, these structures suggest that there is no central binding site for the structurally disparate natural product ligands for both TRP subtypes, namely menthol and capsaicin, respectively. Rather, these molecules bind to distinct regions within the VSLD of each channel. While the structure of TRPA1 is ligand-free (approximately 4 Å), cryo-EM, along with mutagenesis studies of the key Phe909 residue, suggests that the natural product agonist allyisothiocyanate (AITC) and antagonist A-967079 bind to sites defined by residues in S5, S6, and the pore helix, also suggesting that the prototypical natural TRP channel agonists bind to distinct pockets for their respective subtypes.

[0185]

[0212] To rationalize the selectivity of this compound, compound 14 was docked into TRPA1 and TRPV1, and these results were compared with the docked pose (pre-MD) of compound 14 docked into TRPM8 (docking energy with TRPM8: -9.9 kcal / mol). As shown in Figure 9C, the docking pose indicates that compound 14 forms extensive interactions with TRPM8. Several key residues, including Trp798, Arg842, His845, Ile846, Leu1001, and Tyr1005, contributed to the binding of compound 14. Figure 9B shows the interaction between compound 14 and TRPA1. The binding pocket of TRPV1 revealed a unique density within the pocket formed by S5, S6, and the first pore helix, including Phe909 (pore helix 1), Leu881 (S5), Ile878 (S5), Phe877 (S5), and Thr874 (S5), which is consistent with the reported binding site. Analysis of the interactions revealed that Thr874 forms a hydrogen bond with compound 14, while Phe909, Leu881, Ile878, and Leu871 contribute to hydrophobic interactions. Figure 9D shows the binding pose of compound 14 in TRPV1. The pocket in TRPV1 is formed by five transmembrane domains from two adjacent monomers, including S3, S4, the S4-S5 linker, S5, and S6. Several key residues in the binding pocket, including Tyr511 (S3), Leu515 (S3), Leu574 (S4), Thr550 (S4), Arg557 (S4-S5 linker), Glu570 (S5 of the first monomer), and Leu672 (S6 of the second monomer), are shown in Figure 9D. Thr550 formed a strong hydrogen bond with compound 14, while Leu515 and Leu574 were found to form hydrophobic contacts with compound 14. The docking energies of compound 14 with TRPM8, TRPA1, and TRPV1 were −9.9 kcal / mol, −7.1 kcal / mol, and −8.3 kcal / mol, respectively, indicating that compound 14 should preferentially bind to TRPM8. High-throughput FLIPR assays in Table 3 showed that compound 14 was moderately selective (13-fold) for TRPM8 over TRPA1 and TRPV1.

[0186]

[0213] A metabolic stability study of compound 14 was performed in mouse liver microsomes to determine its suitability as an in vivo TRPM8 chemical probe. Compound 14 exhibited a half-life (t 1 / 2 ) and an intrinsic clearance (CL) of 0.0455 mL / min / mg int ) and exhibits sufficient metabolic stability for behavioral assays (Table S5). Compound 14 undergoes CYP450 hydroxylation of the spiro or aromatic ring, resulting in t 1 / 2 = 30 minutes.

[0187] Table S5. Stability of compound 14 in mouse liver microsomes. [Table 10]

[0188]

[0214] Example 10 - In vivo analysis.

[0215] Tremor Behavior (WDS) Assay. To determine whether the observed ability of compound 14 to effectively inhibit TRPM8 in vitro could also translate to TRPM8-dependent antinociceptive activity in vivo, a "WDS" assay was performed. In this assay, icilin (10 mg / kg i.p.) was injected into mice treated with compound 14 or vehicle. In mice, TRPM8 is known to share high homology with rat TRPM8, which was used in the in vitro assay. Icilin injection in mice produced clear and quantifiable TRPM8-mediated tremor behavior. Compound 14 (1, 30, and 50 mg / kg) or its vehicle was administered subcutaneously (sc) 30 minutes before icilin injection.

[0189]

[0216] Cold allodynia. Increasing evidence suggests that TRPM8 plays a role in a mouse model of chemotherapy-induced neuropathic pain induced by oxaliplatin (OXP), a condition that mimics the cold hypersensitivity caused by chemotherapy-induced peripheral neuropathy (CIPN). Both acute and chronic OXP-induced cold hypersensitivity have been reproduced in rats and correlated with TRPM8 expression and function. Mizoguchi et al. reported that acute cold allodynia after OXP injection in a rodent model was ameliorated by the TRPM8 blockers N-(2-aminoethyl)-N-[4-(benzyloxy)-3-methoxybenzyl]-N'-(1S)-1-(phenyl)ethyl]urea and TC-I2014. Following these findings, we investigated the effects of compound 14 in an OXP-induced cold allodynia model using acetone as the cold stimulus. Considering that the cold pain threshold increases from approximately 12°C to approximately 26°C in OXP-treated patients, acetone stimulation is thought to induce pain in OXP-treated mice.

[0190]

[0217] As shown in Figure 10, compound 14 produces significant, dose-responsive antinociceptive behavior. At the highest dose of 50 mg / kg, compound 14 inhibits WDS-like cold hypersensitivity in mice with efficacy comparable to that observed with a standard analgesic dose of gabapentin (25 mg / kg, sc).

[0191]

[0218] These results suggest that Ca 2+ The antagonist activity of compound 14 in both flux and patch clamp assays mechanistically links it to TRPM8 in a whole animal model, as icilin-induced WDS behavior is not reproducible in TRPM8-null mice. This data demonstrates key attributes for a chemical or pharmacological probe molecule.

[0192]

[0219] Thermal TRPs, including TRPM8, TRPA1, TRPV1, TRPV2, and TRPV4, have been described in the literature as potential new targets for treating chemotherapy-induced peripheral neuropathy (CIPN). Deficits in sensory perception of cold are manifested, inter alia, as cold allodynia, defined as pain experienced from normally innocuous cold stimuli, and cold hyperalgesia, defined as an increased pain response from painful cold stimuli. Such cold sensation impairments are clinically observed in chemotherapy-induced allodynia, neuropathic pain, complex regional pain syndrome, and painful bladder syndrome. Abnormal acute sensory responses to cold exposure occur after first-dose treatment with the chemotherapeutic agent oxaliplatin, the most commonly used antitumor treatment for colorectal cancer. Furthermore, oxaliplatin promotes increased sensitivity to menthol, likely through overexpression or activation of TRPM8. Colorectal cancer, in particular, is the second leading cause of cancer mortality and the fourth most common malignant disease. Cold sensitivity paresthesia and pharyngeal spasm leading to dysphagia occur as a result of oxaliplatin treatment and are oxaliplatin-related sensory neurotoxicity (sNT). Furthermore, all platinum drugs used to treat lung, testicular, and ovarian cancer, including cisplatin, carboplatin, and oxaliplatin, are known to induce sensory neuropathy.

[0193]

[0220] Heat hyperalgesia is a clinical marker of early-onset oxaliplatin neurotoxicity and can predict severe neurological damage. Cold hypersensitivity is a hallmark of oxaliplatin-induced neuropathy. Preclinically, oxaliplatin-induced hypersensitivity to innocuous and noxious cold stimuli proceeds via a TRPM8-dependent mechanism, as confirmed by knockout studies. TRPM8 blockade with the bifunctional TRPM8 / TRPV1 antagonist capsazepine dose-dependently inhibits oxaliplatin-induced cold allodynia in vivo, an effect not seen with the TRPV1 antagonist 5'-iodoresiniferatoxin. Similarly, TRPM8 mRNA expression in DRGs is significantly increased after cold allodynia induced by a single injection of oxaliplatin, an effect functionally linked to increased responses to TRPM8 stimulation in vivo. These studies are consistent with previous literature reporting similar increases in TRPM8 mRNA expression in L4-L6 DRG after induction of cold hyperalgesia by treatment with oxaliplatin and the oxaliplatin metabolite oxalate. In vitro, TRPM8 mRNA levels were also significantly increased in oxaliplatin-treated DRG neurons. Compound 14 was evaluated for its ability to block sensory responses to cold in an oxaliplatin-induced peripheral neuropathic pain model because cold hypersensitivity is a hallmark of oxaliplatin-induced neuropathy. Despite the development of newer, more targeted chemotherapy cancer treatments, there are currently no pharmacological therapies for CIPN. Duloxetine, used for diabetic neuropathy, only has modest analgesic effects in patients with oxaliplatin-induced CIPN.

[0194]

[0221] The activity of compound 14 was evaluated 7 days after three intraperitoneal injections of OXP (6 mg / kg) in C57 / BL6 mice, when cold allodynia developed. After a single subcutaneous administration of compound 14 (0.1 and 1 μg), attenuated cold allodynia became evident at 15 minutes, reaching maximum inhibition 30 minutes after administration in a dose-dependent manner ( FIG. 11 ). This data suggests that compound 14 may be a potential therapeutic scaffold for the treatment of CIPN.

[0195]

[0222] The antinociceptive activity of compound 14 exceeds that of another reportedly potent TRPM8 antagonist, (R)-(-)-10e, in the same assay. (R)-(-)-10e inhibits oxaliplatin-induced nociceptive paw licking behavior when administered po, ​​even at doses >10,000-fold higher. Similarly, tryptophan-based TRPM8 antagonists reverse oxaliplatin-induced cold allodynia in C57 / BL6 mice at the same dose as compound 14, but this effect is short-lived, likely due to the labile ester group. Compound 14 inhibits the effects of OXP by two t 1 / 2 The menthol-like antagonists reported here may be useful chemical tools for exploring the role of TRPM8 in other pain conditions, such as chronic neuropathic pain in vivo (for which the role of this ion channel remains controversial). Such small molecule scaffolds could therefore provide pharmacological treatments for sensory neuropathies.

[0196]

[0223] Briefly, identifying replacement of the (-)-menthyl ring of compound 1 with a lipophilic moiety results in Ca2+ receptor activity, as shown by computational studies of TRPM8 antagonist scaffolds as described herein and performed on the human TRPM8 homology model described above. 2+This will enable the discovery of a new series of small molecule ligands with highly potent hTRPM8 antagonist activity in flux assays and >10-fold selectivity for TRPV1 and TRPA1. These menthol-optimized analogs, along with menthol-based agonists reported by Dendreon (e.g., D-3263) and Proctor & Gamble, which have nanomolar agonist activity at human TRPM8, may find use as chemical probes for investigating TRPM8 pharmacology, structure-function studies, and structural biology studies. This series may also offer potential for pharmacological treatment of oxaliplatin-induced CIPN and other TRPM8-related sensory neuropathies, as compound 14 can attenuate oxaliplatin-induced cold allodynia in vivo. Furthermore, these compounds may aid in the identification of the TRPM8 pharmacophore for the rational design of small molecule ligands and therapeutic scaffolds. One of the most potent analogs identified (compound 14) inhibits Ca 2+ It possesses excellent antagonist activity in both flux and patch clamp assays and can dose-dependently inhibit the effects of multiple TRPM8 activators (icilin, menthol, and cold) across a range of in vitro and in vivo assays. Compound 14 is readily accessible synthetically via amidation reactions and lacks a chiral center, further enhancing its attractiveness. Compound 14 is one of the most potent TRPM8 antagonists described to date. The SAR studies described above suggest that its spiro[4.5]decan-8-yl moiety is a preferred scaffold for TRPM8 recognition relative to the cognate ligand (-)-menthol, making it an optimal menthol surrogate. The field awaits TRPM8 structures complexed with menthol-derived antagonists to address the subtleties surrounding channel activation versus inactivation, particularly in the context of natural product-based scaffolds. The antagonist compound 14, along with the menthol analog WS-12, are potential options for these studies to delineate antagonist- versus agonist-mediated molecular events at TRPM8.

[0197]

[0224] All publications, patents, and patent applications mentioned herein, including the references set forth in the list below, are hereby incorporated by reference.

[0198] References 1. Winchester, WJ; Gore, K.; Glatt, S.; Petit, W.; Gardiner, JC; Conlon, K.; Postlethwaite, M.; Saintot, PP; Roberts, S.; Gosset, JR; Matsuura, T.; Andrews, MD; Inhibition of TRPM8 channels reduces pain in the cold pressor test in humans. J. Pharmacol. Exp. Ther. 351, 259-269. 2. Kobayashi, K.; Fukuoka, T.; Obata, K.; Yamanaka, H.; Dai, Y.; Tokunaga, A.; Noguchi, K. (2005) Distinct expression of TRPM8, TRPA1, and TRPV1 mRNAs in rat primary afferent neurons with adelta / c-fibers and colocalization with trk receptors. J. Comp. Neurol. 493, 596-606. 3. Proudfoot, C. J.; Garry, E. M.; Cottrell, D. F.; Rosie, R.; Anderson, H.; Robertson, D. C.; Fleetwood-Walker, S. M.; Mitchell, R. (2006) Analgesia mediated by the TRPM8 cold receptor in chronic neuropathic pain. Curr. Biol. 16, 1591-1605. 4. McKemy, D. D.; Neuhausser, W. M.; Julius, D. (2002) Identification of a cold receptor reveals a general role for TRP channels in thermosensation. Nature 416, 52-58. 5. Janssens, A.; Voets, T. (2011) Ligand stoichiometry of the cold- and menthol-activated channel TRPM8. J. Physiol. 589, 4827-4835. 6. Perez de Vega, M. J.; Gomez-Monterrey, I.; Ferrer-Montiel, A.; Gonzalez-Muniz, R. (2016) Transient Receptor Potential Melastatin 8 Channel (TRPM8) Modulation: Cool Entryway for Treating Pain and Cancer. J. Med. Chem. 59, 10006-10029. 7. Yin, Y.; Wu, M.; Zubcevic, L.; Borschel, W. F.; Lander, G. C.; Lee, S. Y. (2017) Structure of the cold- and menthol-sensing ion channel TRPM8. Science. 359, 237-241. 8. Yin, Y.; Le, S. C.; Hsu, A. L.; Borgnia, M. J.; Yang, H.; Lee, S. Y. (2019) Structural basis of cooling agent and lipid sensing by the cold-activated TRPM8 channel. Science. 363, eaav9334. 9. Andrews, M. D.; Af Forselles, K.; Beaumont, K.; Galan, S. R.; Glossop, P. A.; Grenie, M.; Jessiman, A.; Kenyon, A. S.; Lunn, G.; Maw, G.; Owen, R. M.; Pryde, D. C.; Roberts, D.; Tran, T. D. (2015) Discovery of a Selective TRPM8 Antagonist with Clinical Efficacy in Cold-Related Pain. ACS Med. Chem. Lett. 6, 419-424. 10. Horne, D. B.; Tamayo, N. A.; Bartberger, M. D.; Bo, Y.; Clarine, J.; Davis, C. D.; Gore, V. K.; Kaller, M. R.; Lehto, S. G.; Ma, V. V.; Nishimura, N.; Nguyen, T. T.; Tang, P.; Wang, W.; Youngblood, B. D.; Zhang, M.; Gavva, N. R.; Monenschein, H.; Norman, M. H. (2014) Optimization of potency and pharmacokinetic properties of tetrahydroisoquinoline transient receptor potential melastatin 8 (TRPM8) antagonists. J. Med. Chem. 57, 2989-3004.

[0199] 11. Gavva, N. R.; Davis, C.; Lehto, S. G.; Rao, S.; Wang, W.; Zhu, D. X. (2012) Transient receptor potential melastatin 8 (TRPM8) channels are involved in body temperature regulation. Mol. Pain. 8, 36. 12. Lashinger, E. S.; Steiginga, M. S.; Hieble, J. P.; Leon, L. A.; Gardner, S. D.; Nagilla, R.; Davenport, E. A.; Hoffman, B. E.; Laping, N. J.; Su, X. (2008) AMTB, a TRPM8 channel blocker: evidence in rats for activity in overactive bladder and painful bladder syndrome. Am. J. Physiol. Renal Physiol. 295, F803-810. 13. Horne, D. B.; Biswas, K.; Brown, J.; Bartberger, M. D.; Clarine, J.; Davis, C. D.; Gore, V. K.; Harried, S.; Horner, M.; Kaller, M. R.; Lehto, S. G.; Liu, Q.; Ma, V. V.; Monenschein, H.; Nguyen, T. T.; Yuan, C.; Youngblood, B. D.; Zhang, M.; Zhong, W.; Allen, J. R.; Chen, J. J.; Gavva, N. (2018) Discovery of TRPM8 Antagonist (S)-6-(((3-fluoro-4-(trifluoromethoxy)phenyl)(3-fluoropyridin-2-yl)methyl)carbamo yl)nicotinic acid (AMG 333), a Clinical Candidate for the Treatment of Migraine. J. Med. Chem. 61, 8186-8201. 14. De Caro, C.; Russo, R.; Avagliano, C.; Cristiano, C.; Calignano, A.; Aramini, A.; Bianchini, G.; Allegretti, M.; Brandolini, L. (2018) Antinociceptive effect of two novel transient receptor potential melastatin 8 antagonists in acute and chronic pain models in rat. Br. J. Pharmacol. 175, 1691-1706. 15. Almeida, M. C.; Hew-Butler, T.; Soriano, R. N.; Rao, S.; Wang, W.; Wang, J.; Tamayo, N.; Oliveira, D. L.; Nucci, T. B.; Aryal, P.; Garami, A.; Bautista, D.; Gavva, N. R.; Romanovsky, A. A. (2012) Pharmacological blockade of the cold receptor TRPM8 attenuates autonomic and behavioral cold defenses and decreases deep body temperature. J. Neurosci. 32, 2086-2099. 16. Okamoto, Y.; Ohkubo, T.; Ikebe, T.; Yamazaki, J. (2012) Blockade of TRPM8 activity reduces the invasion potential of oral squamous carcinoma cell lines. Int. J. Oncol. 40, 1431-1440. 17. Willis, D. N.; Liu, B.; Ha, M. A.; Jordt, S. E.; Morris, J. B. (2011) Menthol attenuates respiratory irritation responses to multiple cigarette smoke irritants. FASEB J. 25, 4434-4444. 18. Lin, A. H.; Liu, M. H.; Ko, H. B.; Perng, D. W.; Lee, T. S.; Kou, Y. R. (2017) Inflammatory Effects of Menthol vs. Non-menthol Cigarette Smoke Extract on Human Lung Epithelial Cells: A Double-Hit on TRPM8 by Reactive Oxygen Species and Menthol. Front. Physiol. 8, 263. 19. Patel, R.; Goncalves, L.; Leveridge, M.; Mack, S. R.; Hendrick, A.; Brice, N. L.; Dickenson, A. H. (2014) Anti-hyperalgesic effects of a novel TRPM8 agonist in neuropathic rats: a comparison with topical menthol. Pain 155, 2097-2107. 20. Voets, T.; Owsianik, G.; Janssens, A.; Talavera, K.; Nilius, B. (2007) TRPM8 voltage sensor mutants reveal a mechanism for integrating thermal and chemical stimuli. Nat. Chem. Biol. 3, 174-182.

[0200] 21. Bandell, M.; Dubin, A. E.; Petrus, M. J.; Orth, A.; Mathur, J.; Hwang, S. W.; Patapoutian, A. (2006) High-throughput random mutagenesis screen reveals TRPM8 residues specifically required for activation by menthol. Nat. Neurosci. 9, 493-500. 22. Rath, P.; Hilton, J. K.; Sisco, N. J.; Van Horn, W. D. (2016) Implications of Human Transient Receptor Potential Melastatin 8 (TRPM8) Channel Gating from Menthol Binding Studies of the Sensing Domain. Biochemistry 55, 114-124. 23. Chuang, H. H.; Neuhausser, W. M.; Julius, D. (2004) The super-cooling agent icilin reveals a mechanism of coincidence detection by a temperature-sensitive TRP channel. Neuron 43, 859-869. 24. Autzen, H. E.; Myasnikov, A. G.; Campbell, M. G.; Asarnow, D.; Julius, D.; Cheng, Y. (2018) Structure of the human TRPM4 ion channel in a lipid nanodisc. Science 359, 228-232. 25. Matos-Cruz, V.; Schneider, E. R.; Mastrotto, M.; Merriman, D. K.; Bagriantsev, S. N.; Gracheva, E. O. (2017) Molecular Prerequisites for Diminished Cold Sensitivity in Ground Squirrels and Hamsters. Cell. Rep. 21, 3329-3337. 26. Ortar, G.; De Petrocellis, L.; Morera, L.; Moriello, A. S.; Orlando, P.; Morera, E.; Nalli, M.; Di Marzo, V. (2010) (-)-Menthylamine derivatives as potent and selective antagonists of transient receptor potential melastatin type-8 (TRPM8) channels. Bioorg Med. Chem. Lett. 20, 2729-2732. 27. Lampe, T.; Alonso-Alija, C.; Beck, H.; Rosentreter, U.; Sandner, P.; Stahl, E.; Stelte-Ludwig, B. Preparation of substituted 2-benzyloxy-benzoic acid amide derivatives as Cold Menthol Receptor 1 (CMR-1) modulators for treating and preventing urological diseases or disorders. 2007017093 A1. 28. Gavva, N. R.; Klionsky, L.; Qu, Y.; Shi, L.; Tamir, R.; Edenson, S.; Zhang, T. J.; Viswanadhan, V. N.; Toth, A.; Pearce, L. V.; Vanderah, T. W.; Porreca, F.; Blumberg, P. M.; Lile, J.; Sun, Y.; Wild, K.; Louis, J. C.; Treanor, J. J. (2004) Molecular determinants of vanilloid sensitivity in TRPV1. J. Biol. Chem. 279, 20283-20295. 29. Behrendt, H. J.; Germann, T.; Gillen, C.; Hatt, H.; Jostock, R. (2004) Characterization of the mouse cold-menthol receptor TRPM8 and vanilloid receptor type-1 VR1 using a fluorometric imaging plate reader (FLIPR) assay. Br. J. Pharmacol. 141, 737-745. 30. Rami, H. K.; Thompson, M.; Wyman, P.; Jerman, J. C.; Egerton, J.; Brough, S.; Stevens, A. J.; Randall, A. D.; Smart, D.; Gunthorpe, M. J.; Davis, J. B. (2004) Discovery of small molecule antagonists of TRPV1. Bioorg Med. Chem. Lett. 14, 3631-3634.

[0201] 31. Weil, A.; Moore, S. E.; Waite, N. J.; Randall, A.; Gunthorpe, M. J. (2005) Conservation of functional and pharmacological properties in the distantly related temperature sensors TRVP1 and TRPM8. Mol. Pharmacol. 68, 518-527. 32. Knowlton, W. M.; Daniels, R. L.; Palkar, R.; McCoy, D. D.; McKemy, D. D. (2011) Pharmacological blockade of TRPM8 ion channels alters cold and cold pain responses in mice. PLoS One 6, e25894. 33. Andersson, D. A.; Chase, H. W.; Bevan, S. (2004) TRPM8 activation by menthol, icilin, and cold is differentially modulated by intracellular pH. J. Neurosci. 24, 5364-5369. 34. Andersson, D. A.; Nash, M.; Bevan, S. (2007) Modulation of the cold-activated channel TRPM8 by lysophospholipids and polyunsaturated fatty acids. J. Neurosci. 27, 3347-3355. 35. Hilton, J.K.; Salehpour, T.; Sisco, NJ; Rath, P.; Van Horn, WD (2018) Phosphoinositide-interacting regulator of TRP (PIRT) has opposing effects on human and mouse TRPM8 ion channels. J. Biol. Chem. 293, 9423-9434. 36. Bertamino, A.; Ostacolo, C.; Ambrosino, P.; Musella, S.; Di Sarno, V.; Ciaglia, T.; Soldovieri, MV; Iraci, N.; Fernandez Carvajal, A.; de la Torre-Martinez, R.; Ferrer-Montiel, A.; Gonzalez Muniz, R.; Novellino, E.; Taglialatela, M.; Campiglia, P.; Gomez-Monterrey, I. (2016) Tryptamine-Based Derivatives as Transient Receptor Potential Melastatin Type 8 (TRPM8) Channel Modulators. J. Med. Chem. 59, 2179–2191. 37. de la Torre-Martinez, R.; Bonache, MA; Llabres-Campaner, P.J.; Balsera, B.; Fernandez-Carvajal, A.; Fernandez-Ballester, G.; Ferrer-Montiel, A.; Perez de Vega, MJ; Gonzalez-Muniz, R. (2017) Synthesis, high-throughput screening and pharmacological characterization of beta-lactam derivatives as TRPM8 antagonists. Sci. Rep. 7, 10766. 38. Bertamino, A.; Iraci, N.; Ostacolo, C.; Ambrosino, P.; Musella, S.; Di Sarno, V.; Ciaglia, T.; Pepe, G.; Sala, M.; Soldovieri, MV; Mosca, I.; Gonzalez-Rodriguez, S.; Fernandez-Carvajal, A.; Ferrer-Montiel, A.; Novellino, E.; Taglialatela, M.; Campiglia, P.; Gomez-Monterrey, I. (2018) Identification of a Potent Tryptophan-Based TRPM8 Antagonist With in Vivo Analgesic Activity. J. Med. Chem. 61, 6140–6152. 39. Wang, L.; Fu, T.M.; Zhou, Y.; Xia, S.; Greka, A.; Wu, H. (2018) Structures and gating mechanism of human TRPM2. Science 362, eaav4809. 40. De Petrocellis, L.; Ligresti, A.; Schiano Moriello, A.; Iappelli, M.; Verde, R.; Stott, C. G.; Cristino, L.; Orlando, P.; Di Marzo, V. (2013) Non-THC cannabinoids inhibit prostate carcinoma growth in vitro and in vivo: pro-apoptotic effects and underlying mechanisms. Br. J. Pharmacol. 168, 79-102.

[0202] 41. Ha, M. A.; Smith, G. J.; Cichocki, J. A.; Fan, L.; Liu, Y. S.; Caceres, A. I.; Jordt, S. E.; Morris, J. B. (2015) Menthol attenuates respiratory irritation and elevates blood cotinine in cigarette smoke exposed mice. PLoS One 10, e0117128. 42. Tamayo, N. A.; Bo, Y.; Gore, V.; Ma, V.; Nishimura, N.; Tang, P.; Deng, H.; Klionsky, L.; Lehto, S. G.; Wang, W.; Youngblood, B.; Chen, J.; Correll, T. L.; Bartberger, M. D.; Gavva, N. R.; Norman, M. H. (2012) Fused piperidines as a novel class of potent and orally available transient receptor potential melastatin type 8 (TRPM8) antagonists. J. Med. Chem. 55, 1593-1611. 43. Ohmi, M.; Shishido, Y.; Inoue, T.; Ando, K.; Fujiuchi, A.; Yamada, A.; Watanabe, S.; Kawamura, K. (2014) Identification of a novel 2-pyridyl-benzensulfonamide derivative, RQ-00203078, as a selective and orally active TRPM8 antagonist. Bioorg. Med. Chem. Lett. 24, 5364-5368. 44. Caceres, A. I.; Liu, B.; Jabba, S. V.; Achanta, S.; Morris, J. B.; Jordt, S. E. (2017) Transient Receptor Potential Cation Channel Subfamily M Member 8 channels mediate the anti-inflammatory effects of eucalyptol. Br. J. Pharmacol. 174, 867-879. 45. Dodziuk, H.; Jaszunski, M.; Schilf, W. (2005) 1H and 13C NMR chemical shifts and spin-spin coupling constants in trans- and cis-decalins. Magn. Reson. Chem. 43, 639-646. [ PubMed ] 46. Browne , LM ; Klinck , RE ; Stothers, JB (1979) Carbon‐13 NMR Studies: 82.† Carbon‐13 spectra of several 10‐methyl‐cis‐decalins. Conformational preferences of some cis‐decalin derivatives. Org. Magn. Reason. 12, 561-5 47. Player, MR; Parks, DJ; Parsons , W. ; Meegalla, SK; Illig , CR ; Ballentine, SK Heterocyclic benzimidazoles as TRPM8 modulators. US 20100093788 A1. [ PubMed ] 48. Chaudhary, SS; Kadam, AB; Khairatkar-Joshi, N.; Mukhopadhyay, I.; Karnik, PV; Raghuram , A. ; Rao, SS; Vaiyapuri, TS; Wale, DP; Bhosale, VM; Good, GS; Branch, RR; Thomas, A. (2013) Synthesis and pharmacological evaluation of novel N-aryl-3,4-dihydro-1′H-spiro[chromene-2,4′-piperidine]-1′-carboxamides as TRPM8 antagonists. Bioorg. Med. Chem. Rev. 21, 6542–6 49. Shishido, Y.; Ohmi , M. ; Ando, ​​K. Preparation of azaspiro derivatives as TRPM8 antagonists. WO 2015136947 A1. 50. Klein, A. H.; Iodi Carstens, M.; McCluskey, T. S.; Blancher, G.; Simons, C. T.; Slack, J. P.; Furrer, S.; Carstens, E. (2011) Novel menthol-derived cooling compounds activate primary and second-order trigeminal sensory neurons and modulate lingual thermosensitivity. Chem. Senses 36, 649-658.

[0203] 51. Bodding, M.; Wissenbach, U.; Flockerzi, V. (2007) Characterisation of TRPM8 as a pharmacophore receptor. Cell Calcium 42, 618-628. 52. Zhu, B.; Xia, M.; Xu, X.; Ludovici, D. W.; Tennakoon, M.; Youngman, M. A.; Matthews, J. M.; Dax, S. L.; Colburn, R. W.; Qin, N.; Hutchinson, T. L.; Lubin, M. L.; Brandt, M. R.; Stone, D. J.; Flores, C. M.; Macielag, M. J. (2013) Arylglycine derivatives as potent transient receptor potential melastatin 8 (TRPM8) antagonists. Bioorg. Med. Chem. Lett. 23, 2234-2237. 53. Calvo, R. R.; Meegalla, S. K.; Parks, D. J.; Parsons, W. H.; Ballentine, S. K.; Lubin, M. L.; Schneider, C.; Colburn, R. W.; Flores, C. M.; Player, M. R. (2012) Discovery of vinylcycloalkyl-substituted benzimidazole TRPM8 antagonists effective in the treatment of cold allodynia. Bioorg. Med. Chem. Lett. 22, 1903-1907. 54. Patel, R.; Goncalves, L.; Newman, R.; Jiang, F. L.; Goldby, A.; Reeve, J.; Hendrick, A.; Teall, M.; Hannah, D.; Almond, S.; Brice, N.; Dickenson, A. H. (2014) Novel TRPM8 antagonist attenuates cold hypersensitivity after peripheral nerve injury in rats. J. Pharmacol. Exp. Ther. 349, 47-55. 55. Takaishi, M.; Uchida, K.; Suzuki, Y.; Matsui, H.; Shimada, T.; Fujita, F.; Tominaga, M. (2016) Reciprocal effects of capsaicin and menthol on thermosensation through regulated activities of TRPV1 and TRPM8. J. Physiol. Sci. 66, 143-155. 56. Macpherson, L. J.; Hwang, S. W.; Miyamoto, T.; Dubin, A. E.; Patapoutian, A.; Story, G. M. (2006) More than cool: promiscuous relationships of menthol and other sensory compounds. Mol. Cell Neurosci. 32, 335-343. 57. Karashima, Y.; Damann, N.; Prenen, J.; Talavera, K.; Segal, A.; Voets, T.; Nilius, B. (2007) Bimodal action of menthol on the transient receptor potential channel TRPA1. J. Neurosci. 27, 9874-9884. 58. Story, G. M.; Peier, A. M.; Reeve, A. J.; Eid, S. R.; Mosbacher, J.; Hricik, T. R.; Earley, T. J.; Hergarden, A. C.; Andersson, D. A.; Hwang, S. W.; McIntyre, P.; Jegla, T.; Bevan, S.; Patapoutian, A. (2003) ANKTM1, a TRP-like channel expressed in nociceptive neurons, is activated by cold temperatures. Cell 112, 819-829. 59. Karashima, Y.; Talavera, K.; Everaerts , W. ; Janssens , A. ; Kwan, KY; Friends, R.; Nilius, B.; Voets , T. ( 2009 ) TRPA1 acts as a cold sensor in vitro and in vivo . Proc. Natl. Acad. Sci. U.S.A. 106, 1273–1278. 60. McNamara , CR ; Mandel-Brehm , J. ; Bautista, DM; Siemens , J. ; Deranian , KL ; Zhao, M.; Hayward, NJ; Chong, JA; Julius, D.; Moran, MM; Fanger , CM ( 2007 ) TRPA1 mediates formalin-induced pain . Proc. Natl. Acad. Sci. U.S.A. 104, 13525–13530.

[0204] 61. Klionsky , L. ; Tamir , R. ; Gao, B.; Wang, W.; Immke, DC; Nishimura , N. ; Gavva, NR (2007) Species-specific pharmacology of Trichloro(sulfanyl)ethyl benzamides as transient receptor potential ankyrin 1 (TRPA1) antagonists. Mol. Pain 3 , 62. El Kouhen, R.; Surowy, C. S.; Bianchi, B. R.; Neelands, T. R.; McDonald, H. A.; Niforatos, W.; Gomtsyan, A.; Lee, C. H.; Honore, P.; Sullivan, J. P.; Jarvis, M. F.; Faltynek, C. R. (2005) A-425619 [1-isoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)-urea], a novel and selective transient receptor potential type V1 receptor antagonist, blocks channel activation by vanilloids, heat, and acid. J. Pharmacol. Exp. Ther. 314, 400-409. 63. Diver, M. M.; Cheng, Y.; Julius, D. (2019) Structural insights into TRPM8 inhibition and desensitization. Science 365, 1434-1440. 64. Gao, Y.; Cao, E.; Julius, D.; Cheng, Y. (2016) TRPV1 structures in nanodiscs reveal mechanisms of ligand and lipid action. Nature 534, 347-351. 65. Paulsen, C. E.; Armache, J. P.; Gao, Y.; Cheng, Y.; Julius, D. (2015) Structure of the TRPA1 ion channel suggests regulatory mechanisms. Nature 525, 552. 66. Wei, E. T. (1983) Inhibition of shaking movements in rats by central administration of cholinergic and adrenergic agents. Psychopharmacology (Berl) 81, 111-114. 67. Wei, E. T.; Seid, D. A. (1983) AG-3-5: a chemical producing sensations of cold. J. Pharm. Pharmacol. 35, 110-112. 68. Colburn, R. W.; Lubin, M. L.; Stone, D. J., Jr.; Wang, Y.; Lawrence, D.; D'Andrea, M. R.; Brandt, M. R.; Liu, Y.; Flores, C. M.; Qin, N. (2007) Attenuated cold sensitivity in TRPM8 null mice. Neuron 54, 379-386. 69. Kono, T.; Satomi, M.; Suno, M.; Kimura, N.; Yamazaki, H.; Furukawa, H.; Matsubara, K. (2012) Oxaliplatin-induced neurotoxicity involves TRPM8 in the mechanism of acute hypersensitivity to cold sensation. Brain Behav. 2, 68-73. 70. Ling, B.; Authier, N.; Balayssac, D.; Eschalier, A.; Coudore, F. (2007) Behavioral and pharmacological description of oxaliplatin-induced painful neuropathy in rat. Pain 128, 225-234.

[0205] 71. Mizoguchi, S.; Andoh, T.; Yakura, T.; Kuraishi, Y. (2016) Involvement of c-Myc-mediated transient receptor potential melastati 8 expression in oxaliplatin-induced cold allodynia in mice. Pharmacol. Rep. 68, 645-648. 72. Deuis, J. R.; Dvorakova, L. S.; Vetter, I. (2017) Methods Used to Evaluate Pain Behaviors in Rodents. Front. Mol. Neurosci. 10, 284. 73. Naziroglu, M.; Braidy, N. (2017) Thermo-Sensitive TRP Channels: Novel Targets for Treating Chemotherapy-Induced Peripheral Pain. Front. Physiol. 8, 1040. 74. Jensen, T. S.; Finnerup, N. B. (2014) Allodynia and hyperalgesia in neuropathic pain: clinical manifestations and mechanisms. Lancet Neurol. 13, 924-935. 75. Binder, A.; Stengel, M.; Maag, R.; Wasner, G.; Schoch, R.; Moosig, F.; Schommer, B.; Baron, R. (2007) Pain in oxaliplatin-induced neuropathy--sensitisation in the peripheral and central nociceptive system. Eur. J. Cancer. 43, 2658-2663. 76. Attal, N.; Bouhassira, D.; Gautron, M.; Vaillant, J. N.; Mitry, E.; Lepere, C.; Rougier, P.; Guirimand, F. (2009) Thermal hyperalgesia as a marker of oxaliplatin neurotoxicity: a prospective quantified sensory assessment study. Pain 144, 245-252. 77. Grothey, A. (2003) Oxaliplatin-safety profile: neurotoxicity. Semin. Oncol. 30, 5-13. 78. Kelland, L. (2007) The resurgence of platinum-based cancer chemotherapy. Nat. Rev. Cancer 7, 573-584. 79. Descoeur, J.; Pereira, V.; Pizzoccaro, A.; Francois, A.; Ling, B.; Maffre, V.; Couette, B.; Busserolles, J.; Courteix, C.; Noel, J.; Lazdunski, M.; Eschalier, A.; Authier, N.; Bourinet, E. (2011) Oxaliplatin-induced cold hypersensitivity is due to remodelling of ion channel expression in nociceptors. EMBO Mol. Med. 3, 266-278. 80. Gauchan, P.; Andoh, T.; Kato, A.; Kuraishi, Y. (2009) Involvement of increased expression of transient receptor potential melastatin 8 in oxaliplatin-induced cold allodynia in mice. Neurosci. Lett. 458, 93-95.

[0206] 81. Kawashiri, T.; Egashira, N.; Kurobe, K.; Tsutsumi, K.; Yamashita, Y.; Ushio, S.; Yano, T.; Oishi, R. (2012) L type Ca(2)+ channel blockers prevent oxaliplatin-induced cold hyperalgesia and TRPM8 overexpression in rats. Mol. Pain 8, 7. 82. Ta, L. E.; Bieber, A. J.; Carlton, S. M.; Loprinzi, C. L.; Low, P. A.; Windebank, A. J. (2010) Transient Receptor Potential Vanilloid 1 is essential for cisplatin-induced heat hyperalgesia in mice. Mol. Pain 6, 15. 83. Staff, N. P.; Grisold, A.; Grisold, W.; Windebank, A. J. (2017) Chemotherapy-induced peripheral neuropathy: A current review. Ann. Neurol. 81, 772-781. 84. Shapiro, C. L. (2016) Highlights of Recent Findings on Quality-of-Life Management for Patients With Cancer and Their Survivors. JAMA Oncol. 2, 1401-1402. 85. Moran, M. M.; Szallasi, A. (2018) Targeting nociceptive transient receptor potential channels to treat chronic pain: current state of the field. Br. J. Pharmacol. 175, 2185-2203. 86. Yelm, K. E.; Wos, J. A.; Bunke, G. M.; Frederick, H.; Haught, J. C.; Hoke, S. H.; Sreekrishna, K. T.; Lin, Y. Synthesis of aryl cyclohexane carboxamide derivatives useful as sensates in consumer products. 20170057911 A1. 87. Wos, J. A.; Yelm, K. E.; Bunke, G. M.; Frederick, H. A.; Reilly, M.; Haught, J. C.; Sreekrishna, K. T.; Lin, Y. Synthesis of cyclohexane ester derivatives useful as cooling sensates in consumer products. 2017106279 A1. 88. Moreno, O.; Natarajan, S.; Duncan, D. F. Small-molecule modulators of Trp-p8 activity. 20080255185 A1. 89. SYBYL-X; 1.3 Tripos International, 1699 South Hanley Rd. St. Louis, Missouri, 63144, USA., 2010. 90. Xie, X. Q.; Chen, J. Z.; Billings, E. M. (2003) 3D structural model of the G-protein-coupled cannabinoid CB2 receptor. Proteins 53, 307-319.

[0207] 91. Marti-Renom, M. A.; Stuart, A. C.; Fiser, A.; Sanchez, R.; Melo, F.; Sali, A. (2000) Comparative protein structure modeling of genes and genomes. Annu. Rev. Biophys. Biomol. Struct. 29, 291-325. 92. Chen, J. Z.; Wang, J.; Xie, X. Q. (2007) GPCR structure-based virtual screening approach for CB2 antagonist search. J. Chem. Inf. Model. 47, 1626-1637. 93. Feng, Z.; Alqarni, M. H.; Yang, P.; Tong, Q.; Chowdhury, A.; Wang, L.; Xie, X. Q. (2014) Modeling, molecular dynamics simulation, and mutation validation for structure of cannabinoid receptor 2 based on known crystal structures of GPCRs. J. Chem Inf. Model. 54, 2483-2499. 94. Teramachi, J.; Silbermann, R.; Yang, P.; Zhao, W.; Mohammad, K. S.; Guo, J.; Anderson, J. L.; Zhou, D.; Feng, R.; Myint, K. Z.; Maertz, N.; Beumer, J. H.; Eiseman, J. L.; Windle, J. J.; Xie, X. Q.; Roodman, G. D.; Kurihara, N. (2016) Blocking the ZZ domain of sequestosome1 / p62 suppresses myeloma growth and osteoclast formation in vitro and induces dramatic bone formation in myeloma-bearing bones in vivo. Leukemia 30, 390-398. 95. Feng, Z.; Pearce, L. V.; Xu, X.; Yang, X.; Yang, P.; Blumberg, P. M.; Xie, X. Q. (2015) Structural insight into tetrameric hTRPV1 from homology modeling, molecular docking, molecular dynamics simulation, virtual screening, and bioassay validations. J. Chem. Inf. Model. 55, 572-588. 96. Wiederstein, M.; Sippl, M. J. (2007) ProSA-web: interactive web service for the recognition of errors in three-dimensional structures of proteins. Nucleic Acids Res. 35, W407-410. 97. Laskowski, R. A.; MacArthur, M. W.; Moss, D. S.; Thornton, J. M. (1993) PROCHECK: a program to check the stereochemical quality of protein structures. Journal of Applied Crystallography 26, 283-291. 98. Jain, A. N. (1996) Scoring noncovalent protein-ligand interactions: a continuous differentiable function tuned to compute binding affinities. J. Comput. Aided Mol. Des. 10, 427-440. 99. Maier, J. A.; Martinez, C.; Kasavajhala, K.; Wickstrom, L.; Hauser, K. E.; Simmerling, C. (2015) ff14SB: Improving the Accuracy of Protein Side Chain and Backbone Parameters from ff99SB. J. Chem. Theory Comput. 11, 3696-3713. 100. Dickson, C. J.; Madej, B. D.; Skjevik, A. A.; Betz, R. M.; Teigen, K.; Gould, I. R.; Walker, R. C. (2014) Lipid14: The Amber Lipid Force Field. J. Chem. Theory Comput. 10, 865-879.

[0208] 101. Jorgensen, W. L.; Chandrasekhar, J.; Madura, J. D.; Impey, R. W.; Klein, M. L. (1983) Comparison of simple potential functions for simulating liquid water. The Journal of Chemical Physics 79, 926-935. 102. Gotz, A. W.; Williamson, M. J.; Xu, D.; Poole, D.; Le Grand, S.; Walker, R. C. (2012) Routine Microsecond Molecular Dynamics Simulations with AMBER on GPUs. 1. Generalized Born. J.. Chem. Theory Comput. 8, 1542-1555. 103. Salomon-Ferrer, R.; Gotz, A. W.; Poole, D.; Le Grand, S.; Walker, R. C. (2013) Routine Microsecond Molecular Dynamics Simulations with AMBER on GPUs. 2. Explicit Solvent Particle Mesh Ewald. J. Chem. Theory Comput. 9, 3878-3888. 104. Case, D.; Cerutti, D.; Cheatham, T.; Darden, T.; Duke, R.; Giese, T.; Gohlke, H.; Goetz, A.; Greene, D.; Homeyer, N. AMBER 16, University of California: San Francisco, 2016. 105. Loncharich, R. J.; Brooks, B. R.; Pastor, R. W. (1992) Langevin dynamics of peptides: the frictional dependence of isomerization rates of N-acetylalanyl-N'-methylamide. Biopolymers 32, 523-535. 106. Izaguirre, J. A.; Catarello, D. P.; Wozniak, J. M.; Skeel, R. D. (2001) Langevin stabilization of molecular dynamics. The Journal of Chemical Physics 114, 2090-2098. 107. Darden, T.; York, D.; Pedersen, L. (1993) Particle mesh Ewald: An N·log(N) method for Ewald sums in large systems. The Journal of Chemical Physics 98, 10089-10092. 108. Essmann, U.; Perera, L.; Berkowitz, M. L.; Darden, T.; Lee, H.; Pedersen, L. G. (1995) A smooth particle mesh Ewald method. The Journal of Chemical Physics 103, 8577-8593. 109. Ryckaert, J. P.; Ciccotti, G.; Berendsen, H. J. C. (1977) Numerical integration of the cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes. Journal of Computational Physics 23, 327-341.

[0209] 110. Yang, P.; Wang, L.; Xie, X. Q. (2012) Latest advances in novel cannabinoid CB(2) ligands for drug abuse and their therapeutic potential. Future Med. Chem. 4, 187-204. 111. Hawkins, G. D.; Cramer, C. J.; Truhlar, D. G. (1996 ) Parametrized Models of Aqueous Free Energies of Solvation Based on Pairwise Descreening of Solute Atomic Charges from a Dielectric Medium. The Journal of Physical Chemistry 100, 19824-19839. 112. Kollman, P. A.; Massova, I.; Reyes, C.; Kuhn, B.; Huo, S.; Chong, L.; Lee, M.; Lee, T.; Duan, Y.; Wang, W.; Donini, O.; Cieplak, P.; Srinivasan, J.; Case, D. A.; Cheatham, T. E., 3rd (2000) Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. Acc. Chem. Res. 33, 889-897. 113. Tsui, V.; Case, D. A. (2000) Theory and applications of the generalized Born solvation model in macromolecular simulations. Biopolymers 56, 275-291. 114. Bashford, D.; Case, D. A. (2000) Generalized born models of macromolecular solvation effects. Annu. Rev. Phys. Chem. 51, 129-152. 115. Sitkoff, D.; Sharp, K. A.; Honig, B. (1994) Accurate Calculation of Hydration Free Energies Using Macroscopic Solvent Models. The Journal of Physical Chemistry 98 1978-1988. 116. Still, WC; Tempczyk, A.; Hawley, RC; Hendrickson, T. (1990) Semianalytical treatment of solvation for molecular mechanics and dynamics. Journal of the American Chemical Society 112, 6127-6129. 117. Weiser, J.; Shenkin, PS; Still, WC (1999) Approximate atomic surfaces from linear combinations of pairwise overlaps (LCPO). Journal of Computational Chemistry 20, 217-230. 118. Hu, J.; Feng, Z.; Ma, S.; Zhang, Y.; Tong, Q.; Alqarni, MH; Gou, X.;

[0210]

[0225] It will be understood that various details of the presently disclosed subject matter can be changed without departing from the scope of the presently disclosed subject matter. Further, the above description is for purposes of illustration only and not limitation.

Claims

1. Formula (I): 【Chemistry 1】 (In the formula, R 1 teeth, 【Chemistry 2】 (selected from the group consisting of A TRPM8 antagonist comprising:

2. Formula (VII): 【Chemistry 3】 The TRPM8 antagonist of claim 1, having the formula:

3. The following formula (IX): 【Chemistry 4】 The TRPM8 antagonist of claim 1, having the formula:

4. Formula (XI): 【Chemistry 5】 The TRPM8 antagonist of claim 1, having the formula:

5. Formula (XII): 【Chemistry 6】 The TRPM8 antagonist of claim 1, having the formula:

6. The following formula (XIV): 【Chemistry 7】 The TRPM8 antagonist of claim 1, having the formula:

7. Formula (XV): 【Chemistry 8】 The TRPM8 antagonist of claim 1, having the formula:

8. A pharmaceutical composition comprising the TRPM8 antagonist of any one of claims 1 to 7 and a pharma- ceutically acceptable vehicle, carrier or excipient.

9. A pharmaceutical composition according to claim 8 for the treatment of pain.

10. The pharmaceutical composition of claim 9, wherein the pain is neuropathic pain.

11. The pharmaceutical composition of claim 9, wherein the pain is allodynia.

12. The pharmaceutical composition of claim 9, wherein the pain is chronic neuropathic pain.

13. The pharmaceutical composition of claim 9, wherein the pain is chemotherapy-induced neuropathic pain.

14. The pharmaceutical composition according to any one of claims 8 to 13, for intravenous, intraperitoneal, intramuscular or subcutaneous injection.

15. A pharmaceutical composition according to any one of claims 8 to 14 for the treatment of humans.

Citation Information

Patent Citations

  • METHOD AND APPARATUS FOR MEASURING FLUID FLOW

    JP2006509184A

  • Small molecule modulator of trp-p8 activity

    JP2009526859A

  • Detection and use of low molecular weight modulators of the cold menthol receptor TRPM8

    JP2012500828A

  • Compounds useful as TRPM8 activity regulators

    JP2014503486A